Introduction {#s1}
============

Metazoans display a large diversity of developmental modes and adult forms. Processes that govern the generation of form, collectively known as patterning, act to regulate cell identity, location, and number ([@bib66]). The mechanisms by which pattern is established and maintained in adult tissues, however, are poorly understood. Planarians are freshwater flatworms capable of remarkable feats of whole-body regeneration and offer the opportunity, as a model system, to generate important insights into the molecular and cellular mechanisms that can generate and maintain adult tissue pattern.

The planarian anterior-posterior (AP) axis has been a target for study of positional information in adult biology. RNA interference (RNAi) approaches have identified genes with regionalized expression domains that are important in AP patterning ([@bib18]; [@bib2]; [@bib46]). Genes with such constitutive regionalized expression and association with pathways with planarian patterning roles are called position control genes or PCGs ([@bib65]; [@bib56]; [@bib17]). PCGs are predominantly expressed in planarian muscle ([@bib65]; [@bib56]; [@bib17]; [@bib58]). A number of PCGs encode evolutionarily conserved signaling proteins, such as members of the FGFRL family and Wnt/ß-catenin pathway components ([@bib46]). For example, inhibition of the *FGFRL* gene *ndl-3* and the *Wnt* gene *wntP-2* led to the formation of ectopic mouths and pharynges in the trunk ([@bib28]; [@bib56]). These findings support a model in which planarian muscle serves as a source of positional information that patterns surrounding tissues, for instance by influencing the specification of resident stem cells called neoblasts and/or the localization of the specified progeny cells of neoblasts ([@bib46]; [@bib65]; [@bib57]; [@bib68]; [@bib4]; [@bib24]).

Some PCGs are expressed in small groups of cells at the extreme ends of the primary axis called the anterior and posterior poles. Organizers, commonly studied in embryogenesis, are groups of cells that influence the fate of their neighboring cells for the production of tissue pattern ([@bib59]; [@bib32]; [@bib13]). Planarian poles function as putative organizers in planarian head and tail patterning ([@bib55]; [@bib62]; [@bib37]; [@bib36]; [@bib48]). The anterior pole expresses *notum*, which encodes a Wnt inhibitory protein ([@bib42]), the transcription factor (TF)-encoding genes *foxD*, *zic-1, islet, pitx* ([@bib23]; [@bib12]; [@bib33]; [@bib55]; [@bib61]; [@bib62]), and *follistatin*, which encodes an Activin-inhibitory protein ([@bib19]; [@bib49]). The posterior pole expresses *wnt1* ([@bib40]), the TF-encoding genes *islet1* ([@bib23]; [@bib33]) and *pitx* ([@bib12]; [@bib33]), and *wnt11-2* ([@bib1]; [@bib21]). Ablation of the anterior pole through inhibition of pole-specifying genes resulted in head patterning defects, including cyclopia and fused brain lobes ([@bib16]; [@bib8]; [@bib11]; [@bib12]; [@bib33]; [@bib55]; [@bib61]; [@bib62]). Ablation of the posterior pole or inhibition of posterior-pole PCGs resulted in tail-patterning defects, such as stunted tails and fused ventral nerve cords ([@bib41]; [@bib1]; [@bib21]; [@bib23]; [@bib12]; [@bib33]).

We used tissue-fragment and single-cell RNA sequencing to determine the anterior- and posterior-pole transcriptomes, respectively, and expanded the known repertoire of genes with enriched expression in these putative organizers. Inhibition of identified genes uncovered a novel patterning role for the gene *nr4A*, which encodes a planarian ortholog of the broadly conserved NR4A nuclear receptor. *nr4A* is expressed broadly in muscle, including strongly in both poles and other muscle cells at the ends of the AP axis. *nr4A* inhibition results in a novel patterning abnormality in which PCG expression domains shift away from the head and tail tips, followed by similar shifts in differentiated tissues during homeostatic turnover in uninjured animals. The *nr4A* phenotype represents a patterning abnormality in which a stable anatomical pattern is not reached and instead iterative duplication of tissues continues to occur. This phenotype reveals how homeostatic placement of pattern-generating cells at a correct location is essential for the maintenance of stable tissue pattern. We conclude NR4A is a transcription factor that helps regulate tissue pattern at both ends of the AP body axis.

Results {#s2}
=======

RNA sequencing identifies new genes expressed at the anterior and posterior poles {#s2-1}
---------------------------------------------------------------------------------

To comprehensively identify genes expressed in the planarian poles, we performed RNA sequencing of anterior and posterior poles from both uninjured animals and regenerating trunks 72 hr post amputation (hpa). To obtain the anterior-pole transcriptome, we surgically isolated anterior poles ([Figure 1A](#fig1){ref-type="fig"}). Differential gene expression analysis identified 203 genes with significantly higher (p~adj~ \<0.05) expression in pole-containing pieces compared to flanking pieces from uninjured animals ([Figure 1A](#fig1){ref-type="fig"}, [Supplementary file 1A](#supp1){ref-type="supplementary-material"}). In the anterior blastema (an unpigmented outgrowth of differentiating tissue), 86 genes had pole-enriched expression (p~adj~ \<0.05) ([Figure 1A](#fig1){ref-type="fig"}, [Supplementary file 1B](#supp1){ref-type="supplementary-material"}). 51 genes had enriched expression in the poles of both uninjured and regenerating animals and these included the previously published anterior-pole genes *foxD*, *notum*, *zic-1*, and *follistatin* ([Figure 1A](#fig1){ref-type="fig"}, [Supplementary file 1A, B](#supp1){ref-type="supplementary-material"}).

![RNA sequencing of head-tip fragments identifies new anterior-pole-enriched genes.\
(**A**) Anterior pole bulk RNA sequencing: RNA sequencing of excised fragments containing the anterior pole ('Pole piece') and adjacent fragments without the pole ('Flanking piece') from uninjured animals and anterior blastemas of regenerating trunks 72 hr post amputation (72hpa) was performed (cartoons, dotted lines are cut planes, and dotted line numbers indicate cut sequence). Scatter plots show results from differential expression analysis, which identified genes with enriched expression (p~adj~ \<0.05) in pole pieces compared to flanking pieces (black data points), including previously published anterior pole genes (red data points). Many genes with enriched expression were identified in both uninjured and 72hpa animals, as shown in the Venn diagram. (**B**) Head expression of anterior pole candidates from RNA sequencing by whole-mount in situ hybridization. Gene names, if present, represent best human BLAST hits; numerical names indicate the Smedv4.1 Dresden transcriptome assembly transcript number (See 'Gene nomenclature' in Materials and methods). Genes in blue were also expressed in the posterior-pole region ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Area imaged is indicated by the box in the cartoon on the left. Scale bar represents 100 μm. (**C**) Co-expression of anterior pole gene candidates with pooled pole markers *notum* and *foxD* by fluorescence in situ hybridization. DAPI nuclear stain in gray. Area imaged is indicated by the box in the cartoon on the left. Scale bar represents 10 μm. Images are representative of results seen in at least four animals.](elife-42015-fig1){#fig1}

Because the posterior pole is diffuse, its excision contains substantial non-pole tissue. Therefore, we utilized single-cell RNA sequencing of cells from uninjured tail tips and from 72 hpa posterior blastemas to obtain the posterior-pole transcriptome ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We used qRT-PCR to identify FACS-isolated single cells expressing *wnt1* and the muscle marker *collagen* to identify pole cells (*wnt1*^+^; *collagen*^+^) and non-pole muscle cells (*wnt1*^-^; *collagen*^+^) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). From 768 cells, 11 posterior pole cells were identified (six from uninjured animals and five from blastemas); 90 non-pole muscle cells (43 from uninjured animals and 47 from blastemas) were used as controls ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Using single-cell differential expression (SCDE) analysis ([@bib26]), we identified 198 genes with significantly higher expression (p\<0.05) in posterior-pole cells compared to non-pole posterior muscle cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, [Supplementary file 1C](#supp1){ref-type="supplementary-material"}). *wnt1*, *pitx*, and *islet1* were in the top 16% of those 198 genes ranked by enrichment in posterior-pole cells ([Supplementary file 1C](#supp1){ref-type="supplementary-material"}).

We assessed the in vivo expression of 133 candidate anterior-pole genes and 96 candidate posterior pole genes by whole-mount in situ hybridization (WISH) and identified 12 new genes expressed in the anterior pole ([Figure 1B](#fig1){ref-type="fig"}) and 10 new genes expressed at the posterior pole ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The new pole genes included those encoding a predicted secreted factor (*kallmann1*), cell-surface receptors (*ror1, ephr4, ephr5, pcdh9, dcc, ddr2*), and transcription factors (*islet2, musculin, nr4A*) ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Interestingly, some of these genes, such as *kallmann1*, *ephr5*, and dd_20026 were expressed in both anterior and posterior poles, identifying molecular similarity between these structures ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, [Supplementary file 1A-C](#supp1){ref-type="supplementary-material"}). We confirmed the expression of the genes in anterior pole cells by their co-expression with the anterior pole markers *notum* and *foxD* ([Figure 1C](#fig1){ref-type="fig"}).

*nr4A* is required for head and tail patterning {#s2-2}
-----------------------------------------------

We utilized RNAi to determine the functions of new pole genes and identified a novel phenotype following inhibition of the gene *nr4A. nr4A* encodes the *S. mediterranea* homolog to proteins of the NR4A nuclear receptor family, which are found broadly in metazoans ([@bib9]; [@bib15]) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). RNAi of *nr4A* resulted in the progressive formation of posterior ectopic eyes in uninjured animals ([Figure 2A](#fig2){ref-type="fig"}). After initiation of *nr4A* RNAi, the distance between the original eyes and the head tip progressively decreased. By 6 weeks of *nr4A* RNAi, an additional eye pair emerged just posterior to the original eyes. As time progressed, the original and second eye pairs became closer to the head tip and decreased in size. A third eye pair, posterior to the second eye pair then appeared, resulting in animals with six eyes. This iterative process continued with ongoing *nr4A* inhibition, generating animals with as many as 10 eyes after 16 weeks of RNAi.

![*nr4A* RNAi leads to head and tail patterning defects.\
(**A**) Images of the heads of live animals at different time points during control and *nr4A* RNAi. Progressive development of posterior ectopic eyes and complete head regeneration at 7 days post amputation (seven dpa) were observed in *nr4A* RNAi. Proportions indicate numbers of animals with phenotype shown over total number of animals. Scale bars represent 150 μm. (**B**) Images of the tails of live animals at 12 weeks of RNAi. Development of an outgrowth at the tail tip and complete tail regeneration without an outgrowth at seven dpa were observed in *nr4A* RNAi. Scale bars represent 150 μm. (**C**) Differentiated tissue marker expression in the head of 9 week RNAi animals by FISH. Ectopic differentiated tissue marker expression is indicated by arrow heads; posteriorly expanded *mag-1*^+^ cells and head tip loss are indicated with brackets. Dotted white lines indicate anterior borders of the heads. Scale bars for images with *laminB*, NB.22.1e, and *mag-1* represent 100 μm; scale bar for images with *ChAT* and dd_3524 represent 200 μm. (**D**) FISH with differentiated tissue markers showed ectopic marker expression in the tails of 9 week *nr4A(RNAi)* animals (arrow heads) compared to 9 week control animals. Scale bars represent 100 μm. Areas imaged are indicated by the box in the cartoons on the left for all panels. Fluorescence images are maximum intensity projections. All images are representative of results seen in at least four animals.](elife-42015-fig2){#fig2}

By 12 weeks of *nr4A* RNAi, uninjured animals developed dorsal outgrowths at their tail tips, suggesting that *nr4A* influences both head and tail tip pattern ([Figure 2B](#fig2){ref-type="fig"}). After transverse amputation of heads and tails, *nr4A(RNAi)* trunk fragments were capable of regenerating heads with normal eye number and tails without outgrowths ([Figure 2A,B](#fig2){ref-type="fig"}), indicating that the *nr4A* phenotype is most readily apparent during tissue turnover associated with maintenance of anatomical pattern.

Using tissue-specific RNA probes and fluorescence in situ hybridization (FISH), we detected patterning abnormalities of multiple differentiated tissues in both the head and the tail of 9 week *nr4A(RNAi)* animals. In addition to ectopic eyes, labeled by an RNA probe to *opsin*, the heads of *nr4A(RNAi)* animals developed internal (along the AP axis) ectopic foci of epidermal cells normally restricted to the animal periphery at the dorsal-ventral (DV)-median plane (*laminB*^+^ and NB.22.1e^+^ cells) ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Marginal adhesive gland cells (*mag-1^+^*) are normally present in a prepharyngeal domain posterior to the eyes and along the body margin posteriorly from this zone ([@bib69]) ([Figure 2C](#fig2){ref-type="fig"}). The distance from the original eyes to the posterior end of the *mag-1^+^* domain was significantly greater in *nr4A(RNAi)* animals than in control animals ([Figure 2C](#fig2){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). FISH with neural markers *ChAT* and dd_3524, which are expressed in the inverted 'U'-shaped cephalic ganglia, showed a loss of the head region between the apex of the head and the anterior aspect of the brain following *nr4A* RNAi ([Figure 2C](#fig2){ref-type="fig"}). This phenotype is consistent with the shortening of the distance between the original eyes and the apex of the head, and the iterative appearance of ectopic posterior eyes with time. These results suggest that *nr4A* inhibition causes a loss of head tip pattern involving shortening of the distance between the anterior end of differentiated tissues and the head tip and posterior expansion of anteriorly restricted tissues.

Similar to the changes we observed in the head, ectopic foci of DV boundary epidermal cells (*laminB*^+^ and NB.22.1e^+^) appeared internally (along the AP axis) in the tails of *nr4A(RNAi)* animals ([Figure 2D](#fig2){ref-type="fig"}). The secretory *mag-1*^+^ cells normally restricted to the body margin around the tail periphery also appeared internally along the midline of tails following *nr4A* RNAi ([Figure 2D](#fig2){ref-type="fig"}), resulting in aberrant tail-tip patterning. These internally mis-localized tissues indicate a similarity between the defects at the anterior and posterior extremities. The mislocalization of differentiated tissues in *nr4A(RNAi)* animals demonstrates that *nr4A* activity is required for normal restriction of tissues to their proper domains at both extreme ends of the AP axis.

*nr4A* inhibition causes shifts in multiple anterior-posterior PCG expression domains {#s2-3}
-------------------------------------------------------------------------------------

The patterning defects in *nr4A(RNAi)* animals led us to examine the expression of patterning genes (PCGs) in these animals. The expression of several genes like *ndl-4*, *sFRP-1*, *notum*, and *foxD* at the anterior end of the AP axis defines the head extremity ([Figure 3A](#fig3){ref-type="fig"}). In uninjured *nr4A(RNAi)* animals analyzed at 9 weeks of RNAi, these expression domains were retracted from the head tip and expanded posteriorly ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). *foxD*^+^; *notum*^+^ anterior pole cells were no longer present in a cluster at the head tip, but instead were found scattered between the eyes ([Figure 3A](#fig3){ref-type="fig"}).

![*nr4A* maintains PCG expression at the head and tail tips.\
(**A**) Eye marker *opsin* and head PCG expression by FISH in control and *nr4A(RNAi)* animals at 9 weeks of RNAi. Inset shows a magnified view of ectopic *notum*^+^; *foxD*^+^ anterior pole cells in *nr4A(RNAi)* animal. Scale bars represent 200 μm. (**B**) Anterior pole regeneration at the anterior blastema at 72 hr post amputation (72hpa) and 7 days post amputation (7dpa) by FISH. DAPI nuclear stain in gray. Scale bars represent 100 μm. (**C**) Tail PCG expression by FISH in control and *nr4A(RNAi)* animals at 9 weeks of RNAi. Scale bar represents 100 μm. (**D**) Diagram summarizing PCG domain shifts in *nr4A* RNAi. Statistically significant shifts of anterior or posterior PCG boundaries in the direction of the arrows are shown. A single asterisk denotes statistically significant area change without significant domain boundary shift. Double asterisks in *wnt11-2* domain denote the disappearance of its posterior-most expression cluster in *nr4A* RNAi. Quantification of PCG expression domain changes is included in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Supplementary file 1D](#supp1){ref-type="supplementary-material"}. Area imaged is indicated by the box in the cartoon on the left for all panels. Images are maximum intensity projections. All images are representative of results seen in at least four animals.](elife-42015-fig3){#fig3}

Similar to the anterior pole domain, the expression domains of PCGs that are broadly expressed in the head and pre-pharyngeal regions, *ndl-2*, *ndl-5*, *ndl-3*, and *wnt2*, were also shifted. Specifically, the anterior boundary of their expression domains was shifted posteriorly from the head tip following *nr4A* RNAi ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). When considered relative to an anatomical landmark - the original eyes - the anterior boundaries of *ndl-2* and *ndl-5* expression domains, for example, were significantly shifted more posteriorly compared to those in control animals ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). *ndk* expression was not excluded from the head tip in *nr4A(RNAi)* animals, but was also expanded more posteriorly ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). Whereas *nr4A* RNAi impacted the expression of many head PCGs, inhibition of head PCGs *fz5/8-4*, *ndk*, *wntA*, and *foxD*, which are required for anterior patterning ([@bib10]; [@bib55]; [@bib62]; [@bib56]), did not lead to detectable *nr4A* expression changes ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Amputated *nr4A(RNAi)* animals were able to regenerate anterior poles by 72hpa ([Figure 3B](#fig3){ref-type="fig"}). However, at 7 days post amputation (7dpa) the anterior-pole-cell cluster was absent from the head tip and instead was disorganized and shifted posteriorly ([Figure 3B](#fig3){ref-type="fig"}). This anterior-pole positioning phenotype is similar to the anterior-pole phenotype we observed in uninjured *nr4A* RNAi ([Figure 3A](#fig3){ref-type="fig"}).

In the posterior, *wnt1* is normally expressed linearly along the midline of the tail tip (the posterior pole). At 9 weeks post-initiation of *nr4A* RNAi, the posterior-most expression domain of *wnt1* was absent, leaving a gap between the tip of the tail and *wnt1* expression ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). Furthermore, the localized expression of *wnt11-2* at the tail tip was also abrogated by *nr4A* RNAi ([Figure 3C](#fig3){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). We also observed an increase in the area of *wnt11-1* expression in the tails of *nr4A(RNAi)* animals ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}).

In the midbody region, *nr4A* RNAi did not significantly affect PCG expression domains. Specifically, the location of the posterior boundaries of the expression domains of *ndl-2*, *ndl-3*, *ndl-5*, and *wnt2* were normal compared to the control ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}), despite the anterior boundaries of their expression domains being shifted ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). Additionally, the length of *ptk7* expression domain, defined by the distance between its anterior and posterior boundaries in the midbody, was not significantly altered by *nr4A* RNAi ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}).

We also examined PCG expression pattern on the DV and medial-lateral axes of *nr4A(RNAi)* animals. The dorsal-specific expression of *bmp4* was largely intact in *nr4A(RNAi)* animals, with an increase in its expression in the esophagus compared with its expression in control animals ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). There was no ectopic ventral *bmp4* expression in *nr4A(RNAi)* animals ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). The midline expression domains of *slit* and *ephR1* were broadened medial-laterally and were disorganized in the head of *nr4A(RNAi)* animals ([Figure 3A](#fig3){ref-type="fig"}). *slit* expression was also reduced in the tail of *nr4A(RNAi)* animals, but its midline expression in the rest of the body was comparable to that of control animals ([Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}). This suggests *nr4A* inhibition does not cause a gross midline-patterning defect, but rather disrupts *slit* expression specifically in the head and tail, likely associated with disruption in the pattern of anterior and posterior poles, which play important roles in midline specification and patterning ([@bib23]; [@bib12]; [@bib33]; [@bib55]; [@bib61]; [@bib62]; [@bib36]).

Taken together, our PCG expression analysis showed that *nr4A* inhibition causes anterior PCGs to shift posteriorly and posterior PCGs to shift anteriorly ([Figure 3D](#fig3){ref-type="fig"}) while largely sparing midbody, midline, and DV PCG expression domains outside of the head and tail ends.

*nr4A* is expressed in muscle and is upregulated at both anterior- and posterior-facing wounds when pattern begins to be reestablished in regeneration {#s2-4}
------------------------------------------------------------------------------------------------------------------------------------------------------

Planarian muscle cells have important roles in expressing positional information to control adult body pattern maintenance and regeneration ([@bib65]; [@bib56]; [@bib57]). Consistent with its role in patterning, *nr4A* was predominantly expressed in planarian muscle in both intact animals and regenerating blastemas ([Figure 4A](#fig4){ref-type="fig"}). A higher proportion of muscle cells expressed *nr4A* in the head and tail than in the pre-pharyngeal region ([Figure 4B](#fig4){ref-type="fig"}). Although its expression was enriched at the ends of the AP axis, including in the posterior pole ([Figure 4C](#fig4){ref-type="fig"}), *nr4A* was also expressed broadly in body-wall muscle ([Figure 4A](#fig4){ref-type="fig"}). Mapping *nr4A* expression onto single-cell expression data ([@bib67]) showed that *nr4A* was most highly expressed in muscle cells, with some expression in neoblasts ([Figure 4D](#fig4){ref-type="fig"}). By using a single-cell sequencing dataset of different muscle cell subtypes ([@bib58]), we found that *nr4A* was expressed in longitudinal, circular, and DV muscle fiber types, but not in intestinal muscle cells ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Similarly, SCDE analysis of *nr4A*-expressing muscle cells using large-scale single-cell RNA sequencing data ([@bib17]) showed no enrichment for fiber-specific transcripts ([Supplementary file 1E](#supp1){ref-type="supplementary-material"}). During regeneration, *nr4A* expression was upregulated by 48 hpa and increased in level at 72 hpa at both anterior- and posterior-facing wound sites ([Figure 4F,G](#fig4){ref-type="fig"}). This expression time-course behavior in regeneration was similar to that of many anterior and posterior PCGs ([@bib64]; [@bib67]) ([Figure 4G](#fig4){ref-type="fig"}). However, unlike canonical muscle-expressed pattering factors, *nr4A* was upregulated at both anterior- and posterior-facing wounds -- having both anterior- and posterior-PCG-like expression dynamics during regeneration ([Figure 4G](#fig4){ref-type="fig"}).

![Planarian *nr4A* is expressed in muscle.\
(**A**) *nr4A* and *collagen* expression and co-expression in body-wall muscle cells in uninjured animals (top) and anterior and posterior bastema 72 hr post amputation (72hpa, bottom) by FISH. Blastema areas imaged are indicated by the boxes in the cartoon on the right. Uninjured image scale bar represents 100 μm. 72hpa image scale bar represents 50 μm. (**B**) Quantification of proportion of *collagen*^+^ muscle cells that expressed *nr4A* by FISH in the head, pre-pharynx, and tail ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), with a representative image showing *collagen* and *nr4A* double-positive cells (arrow heads). Numbers on the plot indicate mean proportions for each region. Statistical comparisons were done using Brown-Forsythe and Welch ANOVA tests with Dunnett's T3 multiple comparisons test. Scale bar represents 25 μm. (**C**) *nr4A* and *wnt1* expression and co-expression (arrow heads) in the posterior pole in uninjured animals by FISH. Area imaged is indicated by the box in the cartoon on the left. Scale bar represents 10 μm. (**D**) *nr4A* expression in single-cell clusters. Expression of *nr4A* mapped on the t-distributed Stochastic Neighbor Embedding (t-SNE) plot of cell type clusters generated by Seurat ([@bib67]). Muscle and neoblast clusters are labeled. (**E**) *nr4A* expression in muscle cell clusters (left) generated from single-cell RNA sequencing data in [@bib58]; t-SNE representation of major muscle classes is on the right. (**F**) *nr4A* expression in uninjured animal and regenerating trunks at 16 hr post amputation (16hpa), 48hpa, 72 hpa, and 7 days post amputation (7dpa) by whole-mount in situ hybridization. All images are representative of results seen in at least four animals. (**G**) *nr4A* expression levels during anterior and posterior regeneration compared with PCG expression levels. Heat maps were generated with normalized expression levels (expression z-score) of *nr4A* and anterior and posterior PCGs during head (anterior) and tail (posterior) regeneration using previously published data ([@bib67]), and clustered by their trend of expression from 0 to 120 hr post amputation (hpa) with Spearman\'s correlation. *nr4A* clusters with anterior PCGs during anterior regeneration and posterior PCGs during posterior regeneration.\
10.7554/eLife.42015.014Figure 4---source data 1.Quantification of proportion of *collagen*^+^ muscle cells that express *nr4A* in head, pre-pharynx, and tail of uninjured animals.](elife-42015-fig4){#fig4}

*nr4A* regulates the expression of muscle-specific markers and head and tail PCGs {#s2-5}
---------------------------------------------------------------------------------

Because *nr4A* encodes a transcription factor, we reasoned transcriptional changes in the head and tail tips of *nr4A(RNAi)* animals, such as changes in muscle-expressed patterning genes, might precede and explain the patterning phenotype observed. To identify such gene expression changes, we collected head and tail regions for RNA sequencing at several time points before gross anatomical changes could be detected: 2, 3, 4, and 5 weeks following the initiation of *nr4A* RNAi ([Figure 5A](#fig5){ref-type="fig"}).

![*nr4A* regulates the expression of muscle-enriched genes and PCGs.\
(**A**) RNA sequencing of control and *nr4A(RNAi)* animals: Diagram shows the collection of heads and tails for RNA sequencing at selected time points during the course of RNAi (see Materials and methods). Cartoon shows amputation planes as dotted lines. Heat maps were generated from the fold-enrichment of expression of genes differentially expressed in the heads or tails of *nr4A(RNAi)* versus control animals. Columns are RNAi time points and rows are individual genes. Heat map regions to the right of the thick gray line indicate statistically significant (p~adj~ \<0.05) expression changes over control. Color-coded column to the left of each heat map indicates whether each gene was muscle-enriched (salmon) or not muscle-enriched (cyan), as previously determined ([@bib67]). Gene names in bold are PCGs; gene names with an asterisk are genes with significant expression changes in both the head and tail in *nr4A* RNAi compared to control. See Materials and methods for gene nomenclature. (**B**) Expression patterns of a subset of genes regulated by *nr4A* in both the head and the tail and their downregulation by *nr4A* RNAi, shown by FISH. All animals were analyzed at 9 weeks of RNAi. Dotted lines mark animal boundaries. Images are maximum intensity projections, and representative of results seen in at least three animals. Scale bars represent 150 μm.](elife-42015-fig5){#fig5}

We identified 56 and 41 genes with significant expression changes in the head and tail (p~adj~ \<0.05), respectively, in at least one time point in *nr4A(RNAi)* animals compared to controls ([Figure 5A](#fig5){ref-type="fig"}). The majority of these genes (49/56 in the head and 36/41 in the tail) were downregulated and most (32/56 in the head and 19/41 in the tail) were genes known to have muscle-enriched expression from available single-cell RNA sequencing data on wild-type animals ([@bib67]) ([Figure 5A](#fig5){ref-type="fig"}). 16 genes were significantly affected by *nr4A* in both the head and the tail. A high proportion (11/16) of those (e.g., dd_9565 (*col21a1*) and dd_11601 (*qki*)) were genes known to be expressed in muscle ([@bib67]). We verified the decrease in the expression of many of these genes following *nr4A* RNAi with FISH ([Figure 5B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Whereas *nr4A* RNAi reduced the body-wide expression of some genes (e.g., dd_9565 (*col21a1*), dd_1706 (*psapl1*)), it inhibited the expression of other genes more specifically in the head and tail (e.g., dd_2972, dd_11683 (*ca12*), dd_950 (*vim*)) ([Figure 5B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). One of them, dd_950 (*vim*), was expressed in the epidermis ([Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}). We also analyzed the expression patterns of genes with expression affected by *nr4A* RNAi using available RNA sequencing data from different AP axis segments ([@bib60]) ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). One-third of the *nr4A*-regulated genes, including 9 of 16 genes affected by *nr4A* in both the head and the tail, were enriched in their expression in the head and the tail compared to midbody regions ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

###### Magnified image stack showing dd950(*vim*) expression (magenta) and epidermal nuclei (DAPI, gray) in control animal head by FISH.

10.7554/eLife.42015.017

###### Magnified image stack showing dd950(*vim*) expression (magenta) and epidermal nuclei (DAPI, gray) in *nr4A(RNAi)* animal head by FISH.

10.7554/eLife.42015.018

Among the genes with muscle-enriched expression affected by *nr4A* RNAi were several PCGs ([Figure 5A](#fig5){ref-type="fig"}). Following initiation of RNAi, *ndl-2* and *ndl-5* were downregulated in the head (by week 3 and 4, respectively), *wnt11-1* was upregulated in the tail (by week 2), and *nlg-8* was downregulated in the tail (by week 3). These findings are consistent with our FISH studies of the *nr4A(RNAi)* phenotype ([Figure 3A,C](#fig3){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). These genes encode FGFRL (*ndl-2,--5*), Wnt (*wnt11-1*), and Bmp-regulatory (*nlg-8*) proteins and have been implicated in patterning ([@bib35]; [@bib21]; [@bib28]; [@bib56]). These data show that *nr4A* is required for the expression of numerous muscle-expressed genes at the planarian head and tail ends, including those encoding extracellular matrix proteins and PCGs.

Long-term *nr4A* RNAi causes head-specific reduction in muscle progenitor incorporation {#s2-6}
---------------------------------------------------------------------------------------

Because a number of genes with muscle-enriched expression were downregulated following *nr4A* RNAi, we examined muscle fibers in these animals using the 6G10 muscle antibody ([@bib50]). By 9 weeks of RNAi, when multiple ectopic eyes were present, uninjured *nr4A(RNAi)* animals showed loss of longitudinal, circular, and diagonal muscle fibers and a decreased number of *collagen^+^* muscle cells in the head compared to control animals ([Figure 6A--C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). By contrast, muscle fibers were not significantly affected in the trunk or tail of *nr4A(RNAi)* animals and *collagen*^+^ muscle cell numbers were normal in *nr4A(RNAi)* animal tails ([Figure 6A--C](#fig6){ref-type="fig"} [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Similar analyses of *nr4A(RNAi)* animals at an earlier time point (4 weeks of RNAi) showed no changes in muscle fibers or *collagen*^+^ cell numbers in the head or tail compared to control animals ([Figure 6A,C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}).

![*nr4A* inhibition leads to muscle loss at the head tip.\
(**A**) Immunofluorescence with muscle antibody (6G10) in the head and tail of control and *nr4A(RNAi)* animals. Areas imaged are on the ventral surface of the animal. Scale bars represent 200 μm. (**B**) Higher magnification views of muscle fibers in the head tip, trunk, and tail of 9 week RNAi animals, and circular and longitudinal muscle fiber quantification in the tail and trunk ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). Proportions in the head pictures indicate the number of animals with phenotype shown over total number of animals examined. Scale bars represent and 25 μm. Statistical comparisons were done using one-tailed Welch's *t*-tests. (**C**) Muscle marker *collagen* expression in the head and tail by FISH and quantification of *collagen*^+^ muscle cell number in a 190 μm x 125 μm area (white box) through the entire DV axis of head and tail tips ([Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). Statistical comparisons were done using one-tailed Welch's t-tests. Scale bars represent 150 μm. (**D**) EdU labeling and *collagen* FISH of 9 week control and *nr4A(RNAi)* animals (left) and quantification of the number of new muscle (EdU^+^; *collagen*^+^) cells in each of the numbered regions (matched by location and area) between control and *nr4A(RNAi)* animals (right) ([Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}). Statistical comparisons were done using two-tailed Welch's *t*-test for cell counts in posterior head region and one-tailed Welch's *t*-tests for cell counts in all other regions. Scale bars represent 150 μm. (**E**) Quantification of the number of new muscle (EdU^+^; *collagen*^+^) cells anterior to the eyes in control animals (blue), and anterior to the original eye pair (red) and to the posterior-most ectopic eye pair (yellow) in *nr4A(RNAi)* animals ([Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}). Statistical comparisons were done using Brown-Forsythe and Welch ANOVA tests with Dunnett's T3 multiple comparisons test. n.s. = not significant at a level of 0.05 for all quantifications. All counting was performed blind. Areas imaged are indicated by the box in the cartoons on the left for all panels. All images are maximum intensity projections, and are representative of results seen in at least four animals per panel.\
10.7554/eLife.42015.024Figure 6---source data 1.Muscle fiber quantifications at 9 weeks of RNAi.\
10.7554/eLife.42015.025Figure 6---source data 2.Quantification of number of *collagen*^+^ muscle cells at the head tip and tail tip of 9 week RNAi animals, and at the head tip of 4 week RNAi animals.\
10.7554/eLife.42015.026Figure 6---source data 3.EdU^+^; *collagen*^+^ quantifications in the head, trunk, and tail.](elife-42015-fig6){#fig6}

EdU labeling was performed at 9 weeks of *nr4A* RNAi to examine new muscle cell production. The numbers of new muscle cells (EdU^+^; *collagen*^+^) in the head tip of *nr4A(RNAi)* animals, but not in the posterior head, trunk, or tail, were significantly decreased compared to similar regions (by location and area) in control animals ([Figure 6D](#fig6){ref-type="fig"}). By contrast, there were no significant differences in the total amount of EdU incorporation (all EdU^+^ cells) in those regions between *nr4A(RNAi)* and control animals ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Comparing the region anterior to the original eyes in *nr4A(RNAi)* animals to the region anterior to the eyes in control animals showed greater reduction in new muscle cell number and reduction in total EdU incorporation ([Figure 6E](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). This finding is consistent with the head tip (distance between head apex and original eyes) size reduction observed in *nr4A(RNAi)* animals ([Figure 2A,C](#fig2){ref-type="fig"}). By contrast, the numbers of new muscle cells anterior to the eyes of controls and anterior to the newest eyes in *nr4A(RNAi)* animals were similar ([Figure 6E](#fig6){ref-type="fig"}). *nr4A(RNAi)* and control animals had comparable numbers of apoptotic cells in similar head tip regions (by location and area) as assessed by TUNEL ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}), suggesting defective progenitor migratory targeting as opposed to increased cell death underlies muscle loss at the head tip.

These findings indicate that *nr4A* was not required in general for muscle progenitor production and differentiation throughout the body. The head-tip-specific muscle progenitor incorporation defect occurred after PCG and other gene expression changes were detected in the *nr4A(RNAi)* RNA sequencing data. Together with the observation that muscle fiber loss was also head-restricted and a late-stage phenotype (absent at 4 weeks of RNAi), these findings suggest loss of muscle cells per se is not the cause of the PCG expression changes that occurred at earlier timepoints in the *nr4A* RNAi.

Early PCG domain shifts in *nr4A* RNAi precede changes in differentiated tissues at the head and tail tips {#s2-7}
----------------------------------------------------------------------------------------------------------

Given that the RNA sequencing results suggest PCG expression shifts precede differentiated tissue pattern changes, we sought to characterize the sequence of PCG expression changes that might underlie the phenotype. Importantly, we found that PCG shifts occurred before changes were visible in differentiated tissues, including changes in head muscle ([Figure 7A--D](#fig7){ref-type="fig"}). Specifically, in the head, *ndl-2* and *ndl-5* expression domains shifted posteriorly relative to the eyes by 3 weeks of *nr4A* RNAi compared to control RNAi ([Figure 7A,B](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). At this time point, the numbers of muscle cells and the appearance of muscle fibers were normal in the heads of *nr4A(RNAi)* animals ([Figure 6A,C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). Mis-positioned anterior pole cells were the earliest abnormalities detected, becoming scattered between the eyes by two weeks after initiation of RNAi ([Figure 7A](#fig7){ref-type="fig"}). This posterior shift of *notum* expression preceded detected changes in the expression of other head PCGs (*ndl-2*, *ndl-4*, *ndl-5*, *sFRP-1*), as well as changes in the distribution of marginal adhesive gland cells ([Figure 7A,B](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). Consistent with our findings that muscle fiber loss at the head tip occurs at late stages of the phenotype (after 4 weeks - [Figure 6A,B](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}), we observed no apparent differences in head tip muscle fibers between control and *nr4A(RNAi)* animals after two weeks of RNAi when pole cells were already gone from this location ([Figure 7C](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}).

![Changes in expression of head and tail PCGs precede changes in differentiated tissues in *nr4A* RNAi.\
(**A**) Head PCG expression by FISH in animals at 2, 3, and 4 weeks of RNAi. Anterior pole cells are indicated by arrow heads. Posterior shifts of the anterior boundary of the *ndl-2* expression domain are indicated by brackets. Quantification is shown in [Supplementary file 1D](#supp1){ref-type="supplementary-material"}. Scale bars represent 100 μm. (**B**) Quantification of *ndl-2* (top) and *ndl-5* (bottom) expression domain shifts in a *nr4A(RNAi)* time course. Statistical comparisons were done using one-tailed Welch's *t*-tests. Negative and positive distances on *y*-axis denote that the position of the anterior boundary of expression domain is anterior and posterior to the eyes, respectively; n.s. = not significant at a level of 0.05. \*=p \< 0.05, \*\*=p \< 0.01, \*\*\*=p \< 0.001. (**C**) Head-on view of head tips stained with muscle antibody 6G10 and *notum* probe at 2 weeks of RNAi. Anterior pole cells are indicated by arrow heads. Scale bars represent 50 μm. (**D**) Tail PCG expression by FISH in animals at 2, 3, and 4 weeks of RNAi. Anterior shifts in the posterior-most domain of *wnt1*^+^ posterior pole and the clustered expression domain of *wnt11-2* at tail tip are indicated by brackets and arrow heads, respectively. Quantification is shown in [Supplementary file 1D](#supp1){ref-type="supplementary-material"}. Scale bars represent 100 μm. Images are maximum intensity projections. All images are representative of results seen in at least four animals per panel.](elife-42015-fig7){#fig7}

In the tail, the posterior pole shifted anteriorly by three weeks after initiation of RNAi ([Figure 7D](#fig7){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). The clustered expression of *wnt11-2* at the tail tip also decreased by this time point ([Figure 7D](#fig7){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). However, no changes in *mag-1*^+^ cells were apparent at this time ([Figure 7D](#fig7){ref-type="fig"}, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}), indicating that similar to the case of the anterior head tip, PCG pattern changes precede differentiated tissue shifts at the posterior extremity of *nr4A(RNAi)* animals.

Even after just one week of *nr4A* RNAi, we observed a quantifiable increase in the distance between *notum*^+^ cells and the head apex ([Figure 8A](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}, non-irradiated). Lethal irradiation kills the cycling cells (neoblasts) that are responsible for the production of all planarian cell types ([@bib6]; [@bib14]; [@bib45]). Irradiation suppressed this earliest detectable posterior shift of *notum*^+^ cells in *nr4A(RNAi)* animals, demonstrating that anterior-pole changes were neoblast-dependent ([Figure 8A](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"} irradiated). SMEDWI-1 is a protein that persists in newly differentiated neoblast progeny ([@bib20]). SMEDWI-1^+^ ectopic anterior pole cells were present at both early (2 weeks) and late (9 weeks) *nr4A* RNAi time points ([Figure 8B](#fig8){ref-type="fig"}), further indicating that new anterior pole cells are continually being targeted to ectopically posterior regions in *nr4A(RNAi)* animals. Relative to the original eyes, the anterior pole cells progressively appeared more posteriorly ([Figures 3A](#fig3){ref-type="fig"}, [7A](#fig7){ref-type="fig"} and [8A](#fig8){ref-type="fig"}).

![Anterior pole cells shift early and contribute to the head patterning phenotype in *nr4A(RNAi)* animals.\
(**A**) Expression of *notum* by FISH in animals fixed 7 days after a single *nr4A* or control(RNAi) feeding and 8 days after lethal gamma irradiation. Distances of individual anterior pole cells to head apex were normalized to distances between the eyes within each animal ([Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}). Statistical comparisons were done with Kruskal-Wallis test with Dunn's multiple comparisons test. Scale bar represents 50 μm. (**B**) FISH with *notum* or *foxD* probe and SMEDWI-1-antibody labeling in the head after 2 and 9 weeks of RNAi. Arrow heads indicate *notum*^+^; SMEDWI-1^+^ or *foxD*^+^; SMEDWI-1^+^ cells. Scale bar represents 50 μm. (**C**) *foxD; nr4A* double RNAi phenotype scoring. Representative live images of animals within each phenotypic category (no ectopic eyes, one ectopic eye pair, and more than one ectopic eye pair) are shown. Numbers of animals with each phenotype in control; *nr4A* and *foxD; nr4A* RNAi are displayed below, with graphic representation of phenotype proportions on the right. Differences in the number of animals seen in each phenotypic category between control; *nr4A* and *foxD; nr4A* RNAi were statistically significant (chi-squared = 67, p\<0.00001, df = 2). Scale bars represent 150 μm. (**D**) qPCR quantification of *nr4A* expression in control, control; *nr4A*, and *foxD; nr4A* RNAi in uninjured animals. Statistical comparisons were done with Brown-Forsythe and Welch ANOVA tests with Dunnett's T3 multiple comparisons test. \* = p\<0.05. n.s. = not significant at a level of 0.05 for all quantifications. Area imaged is indicated by the box in the cartoon on the left for panels A and B. All images are representative of results seen in at least four animals per panel.\
10.7554/eLife.42015.031Figure 8---source data 1.Quantification of anterior pole cell distance from head apex, normalized to inter-eye distance in each animal.](elife-42015-fig8){#fig8}

Anterior-pole shifting impacts head pattern alteration in *nr4A(RNAi)* animals {#s2-8}
------------------------------------------------------------------------------

Evidence suggests that the anterior pole has organizer-like activity that can induce surrounding cells to adopt head tip identity ([@bib55]; [@bib61]; [@bib62]; [@bib36]). We hypothesized that rapid changes in anterior-pole-cell distribution following *nr4A* inhibition could be an important component in the development of the *nr4A(RNAi)* patterning phenotype. New anterior pole cell formation requires the gene *foxD* ([@bib55]; [@bib62]), providing a method to genetically ablate the anterior pole. Uninjured animals were subjected to either *foxD* or control RNAi for 6 weeks to eliminate the anterior pole (a subgroup, \"pole-cut animals\", was subjected to head tip excision to facilitate anterior pole removal). Subsequently, *nr4A* RNAi was added to *foxD* and control(RNAi) groups (10 weeks of *nr4A* RNAi for intact animals and 12 weeks for pole-cut animals) to assess whether ectopic pole cell placement was required for the *nr4A(RNAi)* phenotype. A greater proportion of *foxD*; *nr4A(RNAi)* animals lacked ectopic eyes than did control; *nr4A(RNAi)* animals ([Figure 8C](#fig8){ref-type="fig"}). This result was consistently observed in intact and pole-cut animal groups, and in biological replicates ([Figure 8---figure supplement 1B,C](#fig8s1){ref-type="fig"}). qPCR of animals at the end of the double RNAi period showed similar levels of *nr4A* expression inhibition between *foxD*; *nr4A(RNAi)* and control; *nr4A(RNAi)* groups ([Figure 8D](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1D](#fig8s1){ref-type="fig"}). Taken together with the fact that a posterior shift in anterior pole cells was the earliest observed change in *nr4A(RNAi)* animals, these results indicate that the head patterning defects of *nr4A* RNAi are mediated, at least in part, by the mis-positioning of anterior pole cells.

Head tissue pattern fails to reach a stable state in *nr4A(RNAi)* animals {#s2-9}
-------------------------------------------------------------------------

The iterative appearance of ectopic eyes in *nr4A(RNAi)* animals prompted us to ask if a stable, but different, tissue pattern ever emerged in these animals. Tracking the fates of the eyes in individual animals after extended periods of continuous *nr4A* inhibition (as long as 21 weeks) showed that the original eyes (and even older ectopic eyes) eventually faded and disappeared at the head tip as the phenotype progressed ([Figure 9A](#fig9){ref-type="fig"}, [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). As this process unfolded, eye progenitors iteratively shifted their targeting to the most posterior set of eyes, leaving the anterior eyes to decay. Specifically, there were significantly more new eye cells (*opsin*^+^; SMEDWI^+^) in the newest (posterior) ectopic eyes than in older (more anterior) ectopic eyes ([Figure 9B](#fig9){ref-type="fig"}). The numbers of new eye cells produced in a given unit of time were similar between the eyes of control animals and the newest, posterior ectopic eyes in *nr4A(RNAi)* animals ([Figure 9B](#fig9){ref-type="fig"}). These findings suggest that eye progenitor targeting continued to shift posteriorly after *nr4A* inhibition, iteratively producing ectopic eyes without reaching a stable tissue-pattern state.

![*nr4A* RNAi leads to patterning that fails to reach a stable state.\
(**A**) Disappearance and fusion of eyes after many weeks of *nr4A* RNAi. Single animals were separated and individually imaged over the course of long-term *nr4A* RNAi. The number of days of RNAi at the time image was taken is at the bottom right of each image. Eyes crowded near the head tip in *nr4A(RNAi)* animals were observed to disappear (colored arrow heads in frames in which they appear) or fuse (white brackets). (**B**) Progenitor incorporation into the eyes of RNAi animals. Newly incorporated (*opsin*^+^; SMEDWI-1^+^) cells in each eye were quantified in control, 2-eye-pair *nr4A(RNAi)* animals, and 3-eye-pair *nr4A(RNAi)* animals ([Figure 9---source data 1](#fig9sdata1){ref-type="supplementary-material"}), with representative images of the eyes in each group of animals shown. A magnified image of an eye with *opsin*^+^; SMEDWI-1^+^ cells (arrow heads) is shown at the bottom. Double-positive cells were included in the count if located within the eye itself or within approximately one cell diameter of the eye. Statistical comparisons were done with Brown-Forsythe and Welch ANOVA tests with Dunnett's T3 multiple comparisons test. n.s. = not significant at a level of 0.05. \*\*\*\* = p\<0.0001. (**C**) *nr4A(RNAi)* phenotype model (animals aligned by the position of the original eyes, marked by the blue dotted line): *nr4A* RNAi causes an early posterior shift in anterior pole (green) cells followed by a similar shift in other head PCG domains (red zone), and formation of new tissues at ectopically posterior positions with respect to the original anatomy (e.g., posterior ectopic eyes). As PCG domains continue to shift in relation to anatomy, this process continues iteratively throughout *nr4A* inhibition. Refer to Discussion for a more detailed description.\
10.7554/eLife.42015.034Figure 9---source data 1.SMEDWI-1+; *opsin*+ cell quantification in eyes of control and *nr4A(RNAi)* animals.](elife-42015-fig9){#fig9}

Discussion {#s3}
==========

Anterior- and posterior-pole transcriptomes {#s3-1}
-------------------------------------------

The planarian anterior and posterior poles have been the subjects of recent intense study because of their roles in patterning the head and tail ([@bib46]; [@bib37]; [@bib48]). The poles are specialized muscle cells localized at the midline and at the extreme ends of the AP axis and are specified by transcription factors as discrete structures at the animal ends. Given the role for poles in influencing the pattern of neighboring tissues, the poles have been regarded as organizers in planarian regeneration ([@bib23]; [@bib12]; [@bib33]; [@bib55]; [@bib61]; [@bib62]; [@bib63]).

Using bulk and single-cell RNA sequencing, we identified many new genes expressed in the anterior and posterior poles, including genes expressed in both poles that suggest functional similarities in these cells. For example, dd_13188 (*kallmann1*) is expressed highly specifically in both poles and encodes an extracellular matrix protein implicated in olfactory neuron migration in humans ([@bib51]; [@bib52]). Genes with unique functions in organizers in development and regeneration are of interest for understanding how these regions form and pattern neighboring tissue, and RNA-sequencing approaches like the one defined here could identify the transcriptomes of these regulatory regions of embryos and animals broadly.

*nr4A* is a muscle-expressed transcription factor required for patterning {#s3-2}
-------------------------------------------------------------------------

Planarian *nr4A* is specifically expressed in muscle and is required for AP axial patterning. *nr4A* genes are widely conserved in the animal kingdom, and to our knowledge this is the first report of a role in tissue patterning for a member of the NR4A-family of nuclear receptors. The most striking aspect of the activity of *nr4A* in planarians is its role in homeostatic patterning at both ends of the AP axis. Patterning phenotypes affecting both ends of the AP axis of animals are rare. In planarians, *islet1* is known to be required for both anterior and posterior pole formation ([@bib23]; [@bib33]). Here, we find a unique patterning phenotype affecting pole positioning and differentiated tissue pattern at both extreme ends of the AP axis.

NR4A-subfamily members belong to the broader superfamily of nuclear receptors specific to metazoans ([@bib9]; [@bib15]). Although members of many other subfamilies of nuclear receptors bind to steroid hormones, retinoic acids, fatty acids, and prostaglandins, NR4A-family members are orphan receptors that have been proposed to regulate transcription in a ligand-independent manner ([@bib38]; [@bib9]). Whereas vertebrates possess three NR4A members (NR4A1, NR4A2, and NR4A3), many protostomes have only one ([@bib7]). DHR38, the *Drosophila* NR4A ortholog, mediates an atypical ligand-independent ecdysteroid-signaling pathway responsible for molting and metamorphosis ([@bib5]). In vertebrates, three members of the *NR4A* family are immediate-early stress response genes induced by a host of physiological signals such as growth factors, cytokines, prostaglandins, neurotransmitters, and phorbol esters ([@bib34]; [@bib53]). *NR4A1*, *NR4A2*, and *NR4A3* are expressed in a variety of tissues, such as the brain, liver, gonads, skeletal muscle, kidney, fat, lung, and endocrine glands ([@bib34]). In the fields of developmental biology and regeneration, little is known about the role of NR4A transcription factors. *nr4A* was expressed strongly in the planarian head and tail, but was also expressed in muscle cells throughout the body. After amputation, *nr4A* was upregulated at anterior-facing wounds, with timing similar to anterior PCGs, and at posterior-facing wounds, with timing similar to posterior PCGs. RNA-sequencing data from *nr4A(RNAi)* animals revealed that many of the genes dependent on *nr4A* for their expression were specifically expressed in muscle cells, the majority of which encode extracellular matrix (ECM) components (collagens and metalloproteinase) and signaling proteins. Several of these genes predicted to encode ECM components displayed enriched expression in both the head and tail tips. Although it is unknown which genes are direct transcriptional targets of the NR4A protein, genes that experienced changes in expression early in the course of RNAi are more likely to be directly dependent on *nr4A.*

A phenotype that fails to reach a stable pattern {#s3-3}
------------------------------------------------

The planarian AP axis is associated with a continuum of distinct and overlapping PCG expression domains ([@bib18]; [@bib2]; [@bib46]). PCGs promote the production of varying cell types and tissue patterns along the AP axis, for example by promoting eye formation in the head and pharynx formation in the midbody ([@bib28]; [@bib56]). Progenitors for differentiated tissues are specified by the expression of TF genes in neoblasts, generating specialized neoblasts ([@bib47]; [@bib70]). These specialized neoblasts are specified coarsely on the AP axis and produce progenitors that migrate to specific locations or \"target zones\" (TZs) ([@bib4]). For example, eye-specialized neoblasts are specified broadly in the head and pre-pharyngeal regions and migrate to precise locations in the head where eyes form and are maintained ([@bib30]; [@bib31]). Altering PCG pattern with RNAi can result in mis-targeting of progenitors. For example, inhibition of the laterally expressed *wnt5* gene causes eye progenitors to be targeted more laterally than in the wild type, resulting in ectopic lateral eyes ([@bib4]). In addition to migratory targeting of progenitors by extrinsic cues, self-organization of progenitors into their target organ/tissue has a major influence on progenitor targeting ([@bib4]). For example, in instances when an organ and the PCG pattern are discordant (such as during morphallaxis), progenitors can be incorporated into such an organ despite the fact that it is in the incorrect position ([@bib4]; [@bib24]).

We propose a model for the *nr4A(RNAi)* phenotype based upon this prior knowledge and the work presented here. The model involves ectopically posterior tissues in the head and ectopically anterior tissues in the tail manifesting from shifts of the AP positional information away from AP axis ends. This model is described in [Figure 9C](#fig9){ref-type="fig"} and below: Focusing on the head, the AP PCG axis terminus demarcated by the anterior pole shifts internally from the AP anatomical terminus (the head tip) in *nr4A(RNAi)* animals. These pole cells influence gene expression in neighboring muscle so that the entire PCG pattern for the head shifts posteriorly. This results in an animal with a frameshift between the positional information map and the anatomy ([Figure 9C](#fig9){ref-type="fig"}). PCG expression shifting changes the target-zone locations for progenitors. For example, once the target zone for the eye has shifted sufficiently posterior to avoid the self-organizing influence of the original eyes, ectopic posterior eyes appear ([Figure 9C](#fig9){ref-type="fig"}). At this point the original eyes stop receiving progenitors and shrink, as was observed. The head tip shrinks for similar reasons - without the PCG extremity zone coincident with the head tip, less progenitor targeting to the tip leads to its decay during natural tissue turnover ([Figure 9C](#fig9){ref-type="fig"}).

This patterning abnormality continues in an iterative process: new sets of posterior eyes continue to appear and anterior eye sets and the head tip shrink. What underlies this iterative process? We propose that the continuous out-of-register placement of pattern-organizing cells (new pole cells that are part of naturally occurring tissue turnover) in relation to the rest of positional information underlies this process ([Figure 9C](#fig9){ref-type="fig"}). Anterior pole progenitors would continue to be targeted too posteriorly in the changing PCG map. This continues to influence PCG pattern, shifting it even farther posteriorly. Consequently, the extremity continues to decay and the target zone for eye progenitors continues to move posteriorly, with sets of eyes iteratively appearing posteriorly, and anterior sets of eyes decaying because of a lack of progenitor targeting for their renewal. Tracking new eye progenitor incorporation supported this model ([Figure 9B](#fig9){ref-type="fig"}). This process would continuously occur, with equilibrium between PCG pattern and anatomy pattern not attainable. This novel type of patterning phenotype suggests that breaking the concordance between new pattern-organizing cells and pattern itself can lead to a phenotype of continuous pattern-anatomy shifting.

This model depends on PCG-pattern shifts preceding differentiated tissue changes, as was observed. As early as one week after *nr4A* RNAi, the anterior pole began to shift away from the head tip, followed by the posterior pole shifting away from the tail tip at 3 weeks of RNAi. Between 3 and 4 weeks of RNAi, a host of other head and tail PCGs became progressively excluded from head and tail tips. Ectopic eyes, gland, or DV-boundary epidermal cells all appeared later, between 6 and 12 weeks of RNAi. This model is also supported by the finding that ectopic anterior pole cells in *nr4A(RNAi)* animals were newly specified from neoblasts and were required for the *nr4A(RNAi)* phenotype. Ultimately, muscle progenitor targeting to the head tip was reduced in *nr4A(RNAi)* animals, but this occurred after pole and other PCG pattern shifts initiated. This reduction could reflect a general defect in head tip targeting of muscle and other progenitors, perhaps first manifested by the shift in pole progenitor placement, which triggered pattern changes in head muscle.

The *nr4A(RNAi)* phenotype is distinct from prior RNAi phenotypes affecting the number of planarians eyes or pattern at the ends of the AP axis. Unlike *notum* RNAi in uninjured animals, which results in anterior ectopic eyes ([@bib4]; [@bib24]), *nr4A* RNAi generates posterior ectopic eyes. In *ndk* RNAi, ectopic eyes appear in very posterior regions (including the trunk and tail) ([@bib10]), whereas in *nr4A* RNAi, ectopic posterior eyes are restricted to the head. Furthermore, *ndk* RNAi does not lead to a posterior shift in the anterior pole ([@bib56]). Finally, although *islet1* inhibition also affects both poles, its patterning defect during regeneration (versus during homeostasis for *nr4A* RNAi) leads to midline collapse (e.g., cyclopia) ([@bib23]; [@bib33]) that is not observed in *nr4A(RNAi)* animals.

Why would the iterative tissue treadmill-like process of the *nr4A(RNAi)* phenotype stay regionally restricted, without progressing through the body? Whereas PCG expression in the head tip retracted posteriorly, expression boundaries of PCGs outside of the head (e.g., the posterior expression boundary of *ndl-2, ndl-5,* and *wnt2*) did not move posteriorly. Therefore, if head progenitors in general are still made at normal rates (as seen for eye progenitors), one possibility is that more progenitor targeting towards the posterior head could result in growth counterbalancing head tip shrinking.

Our findings regarding the *nr4A(RNAi)* phenotype are consistent with and provide additional evidence for the presence of PCG-defined progenitor target zones that both maintain proper tissue structures during homeostasis and instruct tissue formation at new locations as PCG zones shift, for example, in regeneration ([@bib4]; [@bib24]). Together, our data show that *nr4A* is necessary to maintain the correct location of both the anterior- and posterior-PCG expression zones, consequently maintaining the proper pattern of positional information and differentiated tissues in the head and the tail. We conclude that *nr4A* is a novel adult patterning gene that helps muscle promote the patterning of both the anterior and posterior extreme ends of the primary planarian body axis.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                  Designation                                                                                                                                                                        Source or\                                   Identifiers                                                               Additional\
  (species)\                                                                                                                                                                                                                        reference                                                                                                              information
  or resource                                                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene (*Schmidtea mediterranea*)                *nr4A*; dd_9565 (*col21a1*); dd_3902 (*mmp19*); dd_2972; dd_11683 (*ca12*); dd_508; dd_950 (*vim*); dd_9677 (*pcdh11y*); dd_1706 (*psapl1*); dd_2736 (*hspb1*); dd_11601 (*qki*)   This paper                                   RRID: [NCBITaxon:79327](https://scicrunch.org/resolver/NCBITaxon:79327)   New *Schmidtea mediterranea* genes (*nr4A* and *nr4A*-regulated genes) cloned in this paper. See [Supplementary file 1F](#supp1){ref-type="supplementary-material"} for primer sequences.

  Strain, strain background (ClW4 clonal line)   Asexual strain of *Schmidtea mediterranea*                                                                                                                                         NA                                           RRID: [NCBITaxon:79327](https://scicrunch.org/resolver/NCBITaxon:79327)   All animals used in this study

  Antibody                                       rabbit anti-SMEDWI-1 polyclonal antibody                                                                                                                                           [@bib20]                                     RRID: [AB_2797418](https://scicrunch.org/resolver/AB_2797418)             1:1000 dilution

  Antibody                                       anti-muscle mouse monoclonal 6G10                                                                                                                                                  [@bib50] (DSHB Hybridoma Product 6G10-2C7)   RRID: [AB_2619613](https://scicrunch.org/resolver/AB_2619613)             1:1000 dilution, antibody used for muscle fiber staining

  Commercial assay or kit                        TruSeq RNA Library Prep Kit V2                                                                                                                                                     Illumina                                     RS-122--2001, RS-122--2002                                                Used for bulk RNA sequencing

  Commercial assay or kit                        Nextera XT DNA Library\                                                                                                                                                            Illumina                                     FC-131--1002                                                              Used for single-cell RNA sequencing DNA\
                                                 Preparation Kit                                                                                                                                                                                                                                                                                           library construction

  Commercial\                                    ApopTag Red In Situ Apoptosis Detection Kit                                                                                                                                        Millipore                                    S7165                                                                     Used for TUNEL staining
  assay or kit                                                                                                                                                                                                                                                                                                                                             

  Chemical compound, drug                        F-ara-EdU                                                                                                                                                                          Sigma-Aldrich                                T511293                                                                   Used for EdU labeling

  Software, algorithm                            Prism 8                                                                                                                                                                            GraphPad                                     RRID: [SCR_002798](https://scicrunch.org/resolver/SCR_002798)             Used for all statistical analyses

  Software, algorithm                            Fiji/ImageJ                                                                                                                                                                        NIH, public                                  RRID: [SCR_002285](https://scicrunch.org/resolver/SCR_002285)             Used for all image contrast adjustment\
                                                                                                                                                                                                                                                                                                                                                           and cell, muscle fiber, and PCG domain quantification

  Software, algorithm                            SCDE                                                                                                                                                                               [@bib26]                                     RRID: [SCR_015952](https://scicrunch.org/resolver/SCR_015952)             Used in single-cell RNA sequencing differential expression analysis

  Software, algorithm                            DESeq                                                                                                                                                                              [@bib3]                                      RRID: [SCR_000154](https://scicrunch.org/resolver/SCR_000154)             Used in bulk RNA sequencing differential expression analysis

  Software, algorithm                            MacVector                                                                                                                                                                          MacVector, Inc                               RRID: [SCR_015700](https://scicrunch.org/resolver/SCR_015700)             Used to align protein sequences

  Software, algorithm                            ClustalX                                                                                                                                                                           Clustal                                      RRID: [SCR_017055](https://scicrunch.org/resolver/SCR_017055)             Used to create .phy protein\
                                                                                                                                                                                                                                                                                                                                                           sequence alignment files
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Asexual strain CIW4 of *Schmidtea mediterranea* (RRID: [NCBITaxon:79327](https://scicrunch.org/resolver/NCBITaxon:79327)) was used for all experiments. Animals were starved 7--14 days before experiments.

Bulk RNA sequencing {#s4-2}
-------------------

Cut animal fragments were diced with a scalpel, homogenized using Qiagen TissueLyser III, and RNA was extracted using TRIzol (Life Technologies) according to the manufacturer's protocol. Between 0.5 and 1 μg of RNA was used for cDNA sequencing library synthesis using TruSeq RNA Library Prep Kit V2 (Illumina) following the manufacturer's protocol. Libraries were sequenced on Illumina HiSeq for an average sequencing depth of 20--30 million reads per replicate sample. Libraries were mapped to the dd_Smed_v4 transcriptome (<http://planmine.mpi-cbg.de>) using bowtie 1 ([@bib29]) with -best alignment parameter. Pairwise differential expression analysis was performed using DESeq ([@bib3]) (RRID: [SCR_000154](https://scicrunch.org/resolver/SCR_000154)). Sequencing data and DESeq analysis available in NCBI/GEO (accession GSE121048).

Single-cell RNA sequencing and expression analysis {#s4-3}
--------------------------------------------------

Cut animal fragments were diced with a scalpel, macerated with collagenase treatment, stained with Hoechst (1:25) and propidium iodide (1:5000) and 2C (differentiated, non-dividing) viable (Hoechst^+^; propidium iodide^-^) cells were sorted ([@bib22]) one cell per well by fluorescence activated cell sorting on 96-well plates containing 5 μL of Buffer TCL with 1% 2-mercaptoethanol. Single-cell RNA sequencing libraries were prepared via the SmartSeq2 method, as previously described ([@bib43]; [@bib44]). Briefly, a poly-dT oligo and a template-switching oligo were used for reverse transcription. After cDNA amplification, single-cell cDNA libraries were fragmented and tagged using the Nextera XT kit (Illumina). Single-cell cDNA libraries were then qRT-PCR screened for *wnt1* and *collagen* expression with the primers provided in [Supplementary file 1F](#supp1){ref-type="supplementary-material"}. Posterior pole cells with *wnt1* expression (11) and muscle cells with *collagen* but no *wnt1* expression (90) were selected for were sequencing on Illumina HiSeq for an average of 1--2 million reads per cell. Differential expression analysis of gene expression between pole cells and non-pole cells was performed using the Single-Cell Differential Expression (SCDE, RRID: [SCR_015952](https://scicrunch.org/resolver/SCR_015952)) method, as described ([@bib26]). Sequencing data and SCDE analysis available in NCBI/GEO (accession GSE121048).

Gene nomenclature {#s4-4}
-----------------

Previously published and homology-verified planarian genes are in lowercase italics by themselves. Genes not analyzed for homology by phylogenetics but that have strong (E-value \<0.05) human best-BLAST matches have gene identifiers with \"dd\_\" followed by their Smedv4.1 Dresden transcriptome assembly contig number and italicized human best-BLAST match in parentheses. Genes that only have Dresden transcriptome assembly contig identifiers have no human, mouse, or *C. elegans* best BLAST matches.

Phylogenetic analysis {#s4-5}
---------------------

Nuclear receptor family phylogenetic tree was constructed from 114 total protein sequences (including the translated *Schmidtea mediterranea* dd_12229 *nr4*A mRNA sequence) from representative nuclear receptors of all six nuclear receptor subfamilies from eight different species plus *Schmidtea mediterranea*. Their accession numbers are in [Supplementary file 1G](#supp1){ref-type="supplementary-material"}. Protein sequences were aligned by their conserved DNA-binding and ligand-binding domains via maximum likelihood method using PhyML with 1000 bootstrap replicates. Trees were visualized and formatted in FigTree.

Gene cloning {#s4-6}
------------

Primers used to clone *nr4A* and its targets are listed in [Supplementary file 1F](#supp1){ref-type="supplementary-material"}. Genes were cloned from cDNA into the pGEM vector (Promega) and transformed into *E. coli* DH10B by heat shock. Bacteria were plated on agarose plates containing 1:500 carbenicillin, 1:200 Isopropylthio-β-D-galactoside (IPTG), and 1:625 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) for overnight growth. Colonies were screened by colony PCR and gel electrophoresis. Plasmids were extracted from positive (white) colonies and subsequently validated by Sanger sequencing.

Single RNAi dsRNA was transcribed in vitro (Promega reagents) from PCR-generated templates with flanking T7 promoters. It was then precipitated in ethanol, annealed after resuspension in water, and mixed with planarian food (liver). Each animal was fed 2 µL of the liver containing 4--7 µL/mL dsRNA twice every week, with 2--3 days between each feeding. Animals were then fixed seven days after the last feeding. The total amount of dsRNA per feeding per animal was kept constant as described before. Control RNAi used dsRNA against the *C. elegans unc-22* transcript.

In situ Hybridizations {#s4-7}
----------------------

WISH with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) was performed as described ([@bib39]). FISH and post-antibody binding washes and tyramide development were performed as described ([@bib27]). Briefly, animals were killed in 5% NAC and treated with proteinase K (2 μg/ml). Animals were hybridized with RNA probes at 1:800 dilution overnight at 56°C. Samples were then washed twice in pre-hybridization buffer, 1:1 pre-hybridization: 2X SSC, 2X SSC, 0.2X SSC, and PBS with Triton-X (PBST) in that sequence. Blocking was performed in 5% Western Blocking Reagent (Roche) plus 5% heat-inactivated horse serum diluted in PBST solution when anti-DIG, anti-FITC, or anti-DNP antibodies were used. Post-antibody binding washes and tyramide development were performed as described ([@bib27]). Light images were taken with a Zeiss Discovery Microscope. Fluorescent images were taken with a Zeiss LSM700 Confocal Microscope. Fiji/ImageJ (RRID: [SCR_002285](https://scicrunch.org/resolver/SCR_002285)) was used for FISH co-localization analyses and PCG domain quantifications.

Immunostaining {#s4-8}
--------------

Animals were fixed in 4% formaldehyde solution as for in situ hybridization and treated as described ([@bib27]). The muscle antibody 6G10 ([@bib50]) (RRID: [AB_2619613](https://scicrunch.org/resolver/AB_2619613)) was used at 1:1000 dilution in PBSTB (0.1% TritonX, 0.1% BSA), and an anti-mouse-Alexa conjugated antibody (Life Technologies) was used at a 1:500 dilution. The rabbit anti-SMEDWI-antibody (RRID: [AB_2797418](https://scicrunch.org/resolver/AB_2797418)) was used at 1:1000 dilution in PBSTx (0.1% TritonX) with 10% horse serum, and an anti-rabbit-HRP antibody was used at 1:300 dilution in PBSTx (0.1% TritonX) with 10% horse serum.

Cell and expression domain quantification {#s4-9}
-----------------------------------------

All quantification was performed in a condition-blind manner. Statistical analyses were done using Welch's *t*-tests for comparisons between two groups or using Brown-Forsythe and Welch ANOVA tests with Dunnett's T3 multiple comparisons test for comparisons involving more than two groups, unless otherwise specified. For the proportion of muscle cells expressing *nr4A*, the number *collagen*^+^; *nr4A^ +^* cells was divided by the number of *collagen^+^* cells in head tip, pre-pharyngeal region, and tail tip in a 200 μm by 200 μm area through a 15 μm stack ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). The number circular and longitudinal muscle fibers in each animal was counted within a 100 μm x 100 μm image area ([Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}, [Figure 6---figure supplement 1---source data 1](#fig6s1sdata1){ref-type="supplementary-material"}). For muscle cell quantification, *collagen*^+^ cells were counted in a in a 190 μm wide by 125 μm high rectangular area centered around the midline of the tip of the heads and tails in size-matched control and *nr4A(RNAi)* animals (at least four animals per condition), through the entire thickness (DV axis) of the animal ([Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). The numbers of EdU^+^; *collagen*^+^ and EdU^+^ cells were counted in size- and location-matched areas in control and *nr4A(RNAi)* animals through a 72 μm stack for head, posterior head, and tail regions, and a 33 μm stack in the trunk regions ([Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}, [Figure 6---figure supplement 1---source data 2](#fig6s1sdata2){ref-type="supplementary-material"}). Quantification of TUNEL^+^ cells was done in size- and location-matched head tip areas in control and *nr4A(RNAi)* animals through the entire thickness (DV axis) of the animal ([Figure 6---figure supplement 1---source data 3](#fig6s1sdata3){ref-type="supplementary-material"}). Quantification of PCG expression domain shifts between control and *nr4A(RNAi)* animals was done in ImageJ (at least three animals per condition) ([Supplementary file 1D](#supp1){ref-type="supplementary-material"}). Before PCG domain quantification, animal eyes were occluded by black boxes to de-identify their RNAi condition when possible. Images were then randomized and the positions of the anterior or posterior boundaries of PCG expression domains were designated by another individual drawing lines at the boundaries. Distances between the midpoint of the boundary lines to head tip, anterior edge of original eyes, or tail tip were calculated and normalized to animal length. For *sFRP-1*, *wnt11-1*, and *wnt11-2*, curves following their expression boundaries were drawn and areas of their expression domains were calculated and normalized to the entire area of their respective animals. A one-tailed Welch's *t*-test was used to test for PCG boundary recession in *nr4A(RNAi)* animals. The presence of *wnt11-2* cluster of expression at the tail tip was blindly scored as present or absent, and a Fisher's Exact Test was used for statistical analysis. For anterior-pole-to-head-tip quantifications after one week of RNAi, the distance of each *notum*^+^; *collagen*^+^ cell to the apex of the head was measured on Fiji/ImageJ. This distance was divided by the distance between the eyes within each animal for normalization ([Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}). Kruskal-Wallis test with Dunn's multiple comparisons test was used for statistical analysis of anterior-pole-cell-to-head-apex distances between control and *nr4A(RNAi)* animals (at least five animals per condition). For newly incorporated eye cell quantifications, all *opsin*^+^; SMEDWI-1^+^ cells in each eye were counted in control, 2-eye-pair *nr4A(RNAi)* animals, and 3-eye-pair *nr4A(RNAi)* animals ([Figure 9---source data 1](#fig9sdata1){ref-type="supplementary-material"}). Cells were included in the count if located within the eye itself or within approximately one cell diameter of the eye.

RNA sequencing following *nr4A* RNAi {#s4-10}
------------------------------------

Heads and tails of animals subjected to 2, 3, 4, and 5 weeks of control or *nr4A* RNAi were surgically isolated and separately processed for RNA sequencing ([Figure 5A](#fig5){ref-type="fig"}), as described in Bulk RNA sequencing in Materials and methods. Three biological replicates of heads and tails were collected per time point, with six animals pooled within each biological replicate. Gene expression in *nr4A(RNAi)* heads and tails were compared with gene expression in control(RNAi) heads and tails, respectively, within each RNAi time point, as described in Bulk RNA sequencing in Materilas and methods. Sequencing data and DESeq analysis available in NCBI/GEO (accession GSE121048).

Double RNAi {#s4-11}
-----------

Three RNAi groups, control RNAi, control; *nr4A* RNAi, and *foxD; nr4A *RNAi were selected to test the effect of genetic pole ablation on the *nr4A(RNAi)* phenotype. Control RNAi used dsRNA against the *C. elegans unc-22* transcript. Animals in the *foxD; nr4A(RNAi)* group were subjected to only *foxD* RNAi for 6 weeks (two feedings/week) before the addition of *nr4A* RNAi. During this initial single RNAi period, animals in control and control; *nr4A(RNAi)* groups received only control RNAi, with *nr4A* RNAi added to the *control; nr4A(RNAi)* group at the same time as the *nr4A* RNAi in the *foxD; nr4A(RNAi)* group. At the end of the single RNAi period, the anterior poles from some animals were excised with a scalpel as described for anterior pole sequencing. These pole-cut animals were allowed to recover for 3 days before initiating the double RNAi. Double RNAi was performed for a total of 10 weeks (with two feedings/week) for intact animals and 12 weeks for pole-cut animals, with one-half of the total amount of dsRNA being from each kind dsRNA (see single RNAi in Materials and methods). Two biological replicates of double RNAi with uninjured animals and two biological replicates of double RNAi with pole-cut animals were performed.

qPCR {#s4-12}
----

Six trunk fragments per biological triplicate were isolated for each of the RNAi groups (control, control; *nr4A*, and *foxD; nr4A*). The uninjured and pole-cut animal groups were analyzed separately. Tissues were homogenized using Qiagen TissueLyser III, and RNA was extracted using TRIzol according to the manufacturer's protocol, and synthesized into cDNA with reverse transcriptase per manufacturer's protocol. qPCR primers for *nr4A* ([Supplementary file 1F](#supp1){ref-type="supplementary-material"}) were designed to amplify regions outside of the dsRNA sequences for the respective genes. Primers for the housekeeping gene *gapdh* ([Supplementary file 1F](#supp1){ref-type="supplementary-material"}) were used for expression normalization. Expression levels were calculated by the double delta-Ct method, with normalized *nr4A* expression levels in control; *nr4A*, and *foxD; nr4A(RNAi)* groups compared to normalized *nr4A* expression levels in the control(RNAi) group.

EdU labeling {#s4-13}
------------

F-ara-EdU (Sigma) dissolved in DMSO at 50 mg/mL was mixed with liver paste (3:1 liver: planarian water) for a final concentration of 0.5 mg/mL. Animals were fed once with EdU and liver mix and fixed 8 days after as in in situ hybridization. Development was performed with click chemistry, as described ([@bib54]; [@bib25]).

TUNEL assay {#s4-14}
-----------

ApopTag Red In Situ Apoptosis Detection Kit (Millipore) was used for the TUNEL assay. Animals were fixed as for in situ hybridization, incubated overnight at 37°C in terminal deoxynucleotidyl transferase diluted in reaction buffer, washed in stop/wash buffer, rinsed in PBST (0.3% TritonX), and blocked for 30 min in PBSTx containing 5% heat-inactivated horse serum and 5% Western Block Reagent (Roche). Animals were then developed in anti-digoxigenin rhodamine conjugate diluted in block solution overnight at 4°C in the dark.

Irradiation {#s4-15}
-----------

Animals were given lethal irradiation dosage of 6000 rads using a Gammacell 40 dual ^137^cesium source.

Data availability {#s4-16}
-----------------

Bulk and single-cell RNAi sequencing of planarian poles, and bulk RNA sequencing of *nr4A* RNAi animal heads and tails. Li, DJ, McMann, CL, Reddien PW (2018) available at the NCBI Gene Expression Omnibus (Accession no.: GSE121048).
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###### Summary of data from bulk RNA sequencing, single-cell RNA sequencing, PCG domain quantifications, *nr4A* RNAi target screen, and phylogenetic analysis.

(**A**) Anterior-pole-enriched genes in uninjured animals. (**B**) Anterior-pole-enriched genes in anterior blastema of 72hpa trunks. (**C**) Posterior-pole-enriched genes from single-cell sequencing. (**D**) Quantification of PCG and *mag-1* domain shifts in *nr4A* vs. control RNAi. (**E**) *nr4A*^+^ muscle vs. *nr4A*^-^ muscle SCDE. (**F**) Primers used to clone *nr4A* and its target genes, and qPCR primers. (**G**) Nuclear receptor proteins and their accession numbers used in phylogenetic analysis.
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The following dataset was generated:
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Nuclear receptor NR4A patterns the ends of the planarian anterior-posterior axis\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, including: Alejandro Sánchez Alvarado as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Marianne Bronner as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, Li, McMann, and Reddien use a combination of tissue fragments and single-cell RNA-sequencing to search for additional patterning regulators. Their experiments identify new genes expressed at the anterior and posterior poles, of which the authors proceed to analyze the function of a homolog of the orphan nuclear receptor NR4A. Through a sequencing approach, the authors identify factors enriched in anterior and posterior poles (including *nr4a*). They then describe a multi-eye phenotype after *nr4a(RNAi)*, as well as a wide range of polarity control gene perturbations along the A/P axis. Though several transcription factor genes have been shown to be important in polarity for planarians, the authors argue that the *nr4a(RNAi)* phenotype is distinct, suggesting a new class of patterning defects. However, iterative eye formation (toward the head) was also seen in longer-term *notum(RNAi)* animals (Hill and Petersen, 2018) and iterative eye formation (away from the head) was seen in nou-darake(RNAi) animals (Cebriá, et al). The authors also claim that the role of *nr4A* in patterning both ends of the AP axis is unique (subsection "*nr4A* as a new patterning gene", first paragraph), yet *islet1* also affects both anterior and posterior poles (März et al. and Hayashi et al.). In that light, it is our collective opinion that it is not accurate to say that this is a novel phenotype or phenotype class. Although the data are well quantified for the most part, and the work is proficiently executed, key weaknesses as listed below need to be addressed fully before the paper can be considered further for publication in *eLife*.

Essential revisions:

The authors interpret their results to conclude a role of *nr4a* specific to the poles. Yet, the title of the article and the main claims that *nr4a* functions at the poles and affects A/P polarity are somewhat under-supported. An alternative interpretation that fits most (if not all) results is that *nr4a* acts globally, but that the special functions of poles cause the *nr4a(RNAi)* phenotype to be most obvious there first. It is our shared assessment that two general major weaknesses need to be addressed by the authors. The first class can be addressed by experimental approaches, while the second class can be addressed by rewriting parts of the manuscript to better reflect prior published work.

1\) The authors claim that NR4A specifically affects A/P pole cells. Given the global muscle expression of *nr4a* (including in stem cells) and the broad expression of genes differentially expressed after *nr4a(RNAi)*, it seems that another logical model would be that *nr4a* is globally affecting muscle specification, progenitor migration, survival, or function. It could be that a global phenotype (e.g. premature differentiation of migrating progenitors would be consistent) first manifests itself in the A/P poles because these cells are so critical to body organization or because these cells have to migrate the longest distance.

a\) To test whether *nr4a* is globally required for myogenesis, the authors should examine incorporation of new muscle cells in head, trunk, and tail with BrdU or another analog and either muscle progenitor or pan-muscle markers. These experiments would tell us if *nr4a* is important for muscle cell specification and incorporation into the muscle and -- because it could show whether head, trunk, and tail are equally affected -- would help to support the authors model that *nr4a* is functioning in a special way in the head/tail. Alternatively, if the authors\' model supports asymmetric apoptosis or another route to explain the differences, this could be explored.

b\) Figure 3A needs quantification. It could be informative to measure the% of muscle cells that express *nr4A* in the head vs. trunk vs. tail. This would help distinguish whether the apparent head enrichment is higher expression per cell or a higher percentage of *nr4a*+ cells or neither.

c\) Is dorsal/ventral patterning affected by *nr4a(RNAi)*? The title suggests that only A/P polarity is affected, but *slit* appears to be abnormal (indicating medial/lateral perturbation and potentially other disorganization). Are *bmp4-1*^+^ cells in the correct place? The *nr4a* phenotype also looks reminiscent of the *bmp4-1(RNAi)* phenotype eye-wise.

d\) Can the authors demonstrate head/tail enrichment of the genes that are downstream of NR4A? Three (of 100) are claimed to be head/tail enriched (subsection "*nr4A* regulates the expression of muscle-specific markers and head and tail PCGs", second paragraph), but this isn\'t entirely convincing by eye. Is head/tail enrichment supported for this gene set in other available datasets (e.g. Stückemann, et al.)? If the \~100 genes differentially regulated after *nr4a(RNAi)* are largely not head/tail enriched, this could also support a model where *nr4a* is acting everywhere in some process that is first manifested phenotypically in the head/tail.

e\) Did the authors test the function of other new pole genes in tissue patterning, such as the candidate secreted molecule *kallman1*? The section uncovering new pole genes makes a somewhat abrupt transition to *nr4a* given that this group has the leading expertise and screening all twelve anterior-pole-enriched genes requires minimal resources. I think a comment could be made about what work was performed that led to analysis or *nr4a*, especially if other anterior-pole genes did not produce phenotypes.

f\) The authors should quantify the results in Figure 4C and Figure 6C (e.g. \# of fibers in an orientation per unit distance as per Scimone, et al., 2017). This would boost the conclusion that muscles are structurally normal in *nr4A(RNAi)* animals at the early time point (6C) and that defects are head-specific later (4C).

g\) Can the authors clarify the muscle phenotypes in Figure 4C? The text claims \"reduced body wall muscle in the head\" which seems clear from the 9w dorsal but not ventral images which-if anything-show stronger staining in the *nr4a(RNAi)* animal. Also the method for counting cells in this panel is unclear. Number of cells per what area/volume? What region was counted and how was the tip defined?

2\) The presentation of data in Figure 5 and Figure 5---figure supplement 1 was difficult to follow and likely will be challenging for someone outside of the planarian field. A diagram or set of diagrams showing how each domain shifts and changes size (for the significant results only) would dramatically improve the reader\'s ability to integrate all of these different factors and get a global picture of what is happening after loss of *nr4A*.

a\) Do trunk domains (e.g. *ndl-3, ptk-7*) change in size after *nr4A(RNAi)*? Since the animals were all cropped, it was hard to get a sense of this. Based on the other results, I suspect the trunk might be shortened, but it would be helpful to know for sure.

b\) It would be helpful at the end of the section to recap and bring all of the data together into a coherent conclusion. Are all domains shifting toward the trunk? Is the trunk diminished due to expanding poles? Are the data incongruous with different trends for different molecules even in the same space? Are boundaries between domains more blended/overlapping after *nr4A(RNAi)* or is the overall setup of polarity genes the same, just distorted in ratios/sizes?

3\) Could the authors expand their interpretation/description of where *nr4a* fits in the cell signaling and gene regulatory logic underlying anterior-posterior patterning in planarians? The last figure (Figure 7E) provides a nice description of the *nr4a* phenotype, but a mechanistic model (perhaps in addition to the existing summary) of how this transcription factor regulates patterning would be helpful. In the Discussion, the authors touch on known roles of NR4A homologs in ligand-independent processes. Given the striking difference between homeostasis and regeneration in *nr4a(RNAi)* phenotypes, do the authors think *nr4a* functions autonomously? Or, does *nr4a* function depend on regional signals? Is it possible to address this question experimentally? For example, what happens to *nr4a* expression after manipulating other genes involved in cell signaling, such as *ndk, fz5/8-4* or *wntA? nr4a* appears to function as a key intermediary and without its function, differentiation of pole cells shifts anatomically. It would be interesting to explore how the *nr4a* expression domain behaves in reciprocal experiments to those presented in Figure 5 (i.e., knocking down patterning genes and inspecting *nr4a* expression to determine if it changes).

4\) *nr4a* (dd-Smed_v4 or 6_12229) appears to be differentially expressed following *myoD* RNAi (48 hpa). We did not peruse other gene lists, such as those derived from single muscle cell RNA-seq studies, but the *myoD* result indicates that the tissue fragment single-cell RNA-seq approach taken in this paper was important and necessary for uncovering additional pole genes. The authors could discuss whatever links may exist between this work and their previous studies.

10.7554/eLife.42015.041

Author response

> Summary:
>
> In this manuscript, Li, McMann, and Reddien use a combination of tissue fragments and single-cell RNA-sequencing to search for additional patterning regulators. Their experiments identify new genes expressed at the anterior and posterior poles, of which the authors proceed to analyze the function of a homolog of the orphan nuclear receptor NR4A. Through a sequencing approach, the authors identify factors enriched in anterior and posterior poles (including nr4a). They then describe a multi-eye phenotype after nr4a(RNAi), as well as a wide range of polarity control gene perturbations along the A/P axis. Though several transcription factor genes have been shown to be important in polarity for planarians, the authors argue that the nr4a(RNAi) phenotype is distinct, suggesting a new class of patterning defects. However, iterative eye formation (toward the head) was also seen in longer-term notum(RNAi) animals (Hill and Petersen, 2018) and iterative eye formation (away from the head) was seen in nou-darake(RNAi) animals (Cebriá, et al). The authors also claim that the role of nr4A in patterning both ends of the AP axis is unique (subsection "nr4A as a new patterning gene", first paragraph), yet islet1 also affects both anterior and posterior poles (März et al. and Hayashi et al.). In that light, it is our collective opinion that it is not accurate to say that this is a novel phenotype or phenotype class. Although the data are well quantified for the most part, and the work is proficiently executed, key weaknesses as listed below need to be addressed fully before the paper can be considered further for publication in eLife.

We agree with the reviewers that multiple sets of ectopic eyes can be found in *notum* and *ndk(RNAi)* animals, and that worded as such (emphasis on iteration), this is a similarity with the *nr4A(RNAi)* phenotype. However, the nature of the eye iteration phenotype is different in all three cases. This comment was helpful in underscoring the importance to us of comparing our phenotype to other known cases of pattern disruption in the manuscript -- including with additional data (Figure 9A, B, Figure 9---figure supplement 1) and wording improvements (such as the in the Discussion) -- to clarify the nature of the *nr4A(RNAi)* phenotype (and the fact that it is distinct from these other cases). In brief, in the case of *notum* RNAi, ectopic eyes appear anteriorly, whereas in the case of *nr4A* and *ndk* RNAi the ectopic eyes appear posteriorly. In the case of ectopic eyes in *ndk* RNAi the eyes appear in posterior regions (including far into the trunk and the tail) with ever increasing distance from the head tip and anterior pole over time (Cebriá et al., 2002, Figure 3---figure supplement 2A). By contrast, *nr4A* RNAi leads to the appearance of ectopic eyes restricted to the head region, at a confined distance from the head tip and the anterior pole (Figure 2A, Figure 3A, Figure 9, Figure 9---figure supplement 1). In the case of *nr4A* RNAi, the anterior pole moves posteriorly and the head tip to original eye distance shrinks (Figure 3A, Figure 7A, C, Figure 8A, B, Figure 9A, Figure 9---figure supplement 1), whereas this does not happen in *ndk* RNAi (Cebriá et al., 2002, Scimone et al., 2016). Our data therefore suggest that fundamentally different underlying cellular explanations exist for the *nr4A* and *ndk(RNAi)* phenotypes. With regards to genes impacting both ends of the animal, we agree that is interesting and important to discuss in the text that *islet1* can affect both poles (now mentioned in the Discussion). However, the *islet1(RNAi)* phenotype is also very different from the *nr4A(RNAi)* phenotype. The anterior and posterior patterning phenotype in *islet1* RNAi is reported as a regeneration phenotype that involves midline collapse (fused eyes in the head and fused ventral nerve cords in the tail), associated with disruption of *slit* expression domain in the head and complete abrogation of *wnt1* expression in the tail (Hayashi et al., 2011; März et al., 2013). *nr4A* RNAi results in a homeostatic, not regenerative phenotype that is different in anatomical pattern; for example it does not result in midline collapse or general loss of pole function.

We have now taken the *nr4A(RNAi)* phenotype to the extreme with continuous homeostatic *nr4A* inhibition for as long as 21 weeks (Figure 9A, Figure 9---figure supplement 1). We tracked the fate of the eyes of individual animals throughout the course of our RNAi and in several instances noted clear disappearances of the original eyes at the head tip (Figure 9A, Figure 9---figure supplement 1). We have also observed fusion events between older and newer eyes associated with crowding at the head tip (Figure 9A, Figure 9---figure supplement 1). This is consistent with our model of shifting PCG domains and decreased progenitor targeting to the head tip (Figure 9C), and is different from other patterning phenotypes previously reported.

Taken together, we feel that these features make *nr4A(RNAi)* phenotype a novel phenotype, and hope that new data and wording improvement clarify this phenotype. We understand that the word "class" may be interpreted as wholly distinct from all other patterning phenotypes and have removed it from our description to avoid that misconception.

> Essential revisions:
>
> The authors interpret their results to conclude a role of nr4a specific to the poles.

We do not intend our wording to indicate a conclusion that a role of *nr4A* is *specific* to the poles. We do find, however, that the first cellular defect detected following *nr4A* RNAi is a shift in the anterior pole -- perhaps this led to the misperception. Given this comment, we have revised the text carefully throughout to ensure this is not implied inadvertently in our wording.

> Yet, the title of the article and the main claims that nr4a functions at the poles and affects A/P polarity are somewhat under-supported.

The title of our paper was, \"Nuclear receptor NR4A patterns the ends of the planarian anterior-posterior axis,\" which was not intended to be interpreted as \"functions at the poles\" (we would reserve use of the word pole for the anterior/posterior pole cells themselves) or to mean \"affects A/P polarity\" (it does not affect A/P polarity so much as AP pattern). Instead, the intent is that *nr4A* function impacts the pattern of the head end and tail end, and *nr4A* function impacts the location of the anterior and posterior pole cells. To make this clearer we have re-worded the title to read: \"Nuclear receptor NR4A is required for patterning at the ends of the planarian anterior-posterior axis.\"

> An alternative interpretation that fits most (if not all) results is that nr4a acts globally, but that the special functions of poles cause the nr4a(RNAi) phenotype to be most obvious there first. It is our shared assessment that two general major weaknesses need to be addressed by the authors. The first class can be addressed by experimental approaches, while the second class can be addressed by rewriting parts of the manuscript to better reflect prior published work.
>
> 1\) The authors claim that NR4A specifically affects A/P pole cells. Given the global muscle expression of nr4a (including in stem cells) and the broad expression of genes differentially expressed after nr4a(RNAi), it seems that another logical model would be that nr4a is globally affecting muscle specification, progenitor migration, survival, or function. It could be that a global phenotype (e.g. premature differentiation of migrating progenitors would be consistent) first manifests itself in the A/P poles because these cells are so critical to body organization or because these cells have to migrate the longest distance.

We do not intend our wording to claim that NR4A specifically affects A/P pole cells (and have carefully edited the main text to avoid that misperception). Rather, *nr4A* is required to properly pattern the head and tail. We do claim, with support from data, that shifts in the pole cells are the earliest manifestations observed in the *nr4A(RNAi)* phenotype (Figure 7, Figure 7---figure supplement 1, Supplementary file 1D), which also includes broader disruptions in head and tail PCG expression domains as well as in differentiated tissues like the muscle and the epidermis (Figure 2, Figure 2---figure supplement 2, Figure 6, Figure 6---figure supplement 1, Figure 7---figure supplement 1, Supplementary file 1D). Additional data and data analyses to address specific points raised by the reviewers are below.

> a\) To test whether nr4a is globally required for myogenesis, the authors should examine incorporation of new muscle cells in head, trunk, and tail with BrdU or another analog and either muscle progenitor or pan-muscle markers. These experiments would tell us if nr4a is important for muscle cell specification and incorporation into the muscle and -- because it could show whether head, trunk, and tail are equally affected -- would help to support the authors model that nr4a is functioning in a special way in the head/tail. Alternatively, if the authors\' model supports asymmetric apoptosis or another route to explain the differences, this could be explored.

To address this myogenesis question, we utilized EdU to analyze the production of new muscle cells in *nr4A* RNAi and incorporated the results and findings in the revised figures and main text of the manuscript (Figure 6D, E, Figure 6---figure supplement 1C, D).

We observed that at 9 weeks of RNAi the number of EdU; *collagen* double-positive cells (new muscle cells) was significantly lower in the head tip of *nr4A(RNAi)* animals compared to that in a similar region (by location and area) in the head tips of control animals (Figure 6D). In contrast, the number of new muscle cells was not significantly different in the posterior head region, or significantly reduced in the trunk or tail regions of *nr4A(RNAi)* animals compared to those in equivalent regions in control animals (Figure 6D). We also quantified the total EdU incorporation events (not just muscle) in the same head tip, posterior head, trunk, and tail regions (Figure 6---figure supplement 1C), and observed no significant differences between control and *nr4A(RNAi)* animals. If anything, both the number of new muscle cells and total EdU incorporation events in the posterior head region were slightly higher (though not statistically significant) in *nr4A(RNAi)* animals compared to control animals, suggesting a posterior accumulation of new cells and new muscle cells that do not make their way to the head tip.

Furthermore, we quantified the number of new muscle cells and total EdU incorporation events in the head tip area immediately anterior to the eyes in control animals and compared to those in the head tip area immediately anterior to the original (anterior-most) eyes and in the head tip area anterior to the newest (posterior-most) ectopic eyes in *nr4A(RNAi)* animals (Figure 6E, Figure 6---figure supplement 1D). Compared to the numbers in the control animal head tip areas, we observed that the number of new muscle cells and total EdU incorporation events were significantly lower in head tip areas anterior to the original eyes but not significantly different in head tip areas anterior to the newest eyes in *nr4A(RNAi)* animals. This is consistent with the head tip decay with respect to the original eyes observed in *nr4A* RNAi (Figure 2A, C, Figure 9, Figure 9---figure supplement 1).

We also assessed the degree of apoptosis at the head tips by quantifying the number of TUNEL+ cells in equivalent regions (by location and area) in control and *nr4A(RNAi)* animals (Figure 6---figure supplement 1E). We observed no significant increase in apoptosis in the head tips of *nr4A(RNAi)* animals that would contribute the head tip decay.

Together these data identify no general myogenesis defects in *nr4A* RNAi, and reveal a head-tip-specific effect in progenitor targeting. These data are discussed in the text and the Discussion.

> b\) Figure 3A needs quantification. It could be informative to measure the% of muscle cells that express nr4A in the head vs. trunk vs. tail. This would help distinguish whether the apparent head enrichment is higher expression per cell or a higher percentage of nr4a+ cells or neither.

We performed the suggested quantification of the proportion of muscle (*collagen*^+^) cells that express *nr4A* in the head tip, trunk region just anterior to the pharynx, and tail tip (Figure 4B). Whereas *nr4A* is expressed broadly, there is a significantly higher proportion of muscle cells expressing *nr4A* in the head tip and tail tip compared to that in the trunk.

> c\) Is dorsal/ventral patterning affected by nr4a(RNAi)? The title suggests that only A/P polarity is affected, but slit appears to be abnormal (indicating medial/lateral perturbation and potentially other disorganization). Are bmp4-1+ cells in the correct place? The nr4a phenotype also looks reminiscent of the bmp4-1(RNAi) phenotype eye-wise.

In regards to *bmp4, in situ* hybridization analysis of *bmp4* expression in new data did not reveal overt differences in its expression pattern between control and *nr4A(RNAi)* animals (Figure 3---figure supplement 3B). No disruption in the dorsal expression domain of *bmp4* was detected and no ectopic ventral *bmp4* expression was observed in *nr4A* RNAi. *bmp4* expression in the esophagus was stronger in *nr4A(RNAi)* animals compared to control animals, but there were no ectopic foci of *bmp4* expression. Although *bmp4* RNAi in some cases also results in ectopic eyes (Reddien et al., 2007; Molina et al., 2007; Adell et al., 2010), their locations with respect to the original eyes (medial, posterior) differ from the locations of the ectopic eyes (posterior and lateral) in *nr4A* RNAi. Furthermore, we observed iterative appearance of posterior ectopic eyes in *nr4A* RNAi that is not observed in *bmp4* RNAi (Figure 2A, Figure 9, Figure 9---figure supplement 1).

*slit* expression is more disorganized medial-laterally in the head and is reduced in the tail, but its midline expression domain was normal in the midbody (Figure 3A and Figure 3---figure supplement 3C). Given the roles for the poles in specifying the midline (Hayashi et al., 2011, März, et al., 2013, Scimone et al., 2014, and Oderberg et al., 2017), disruption of *slit* expression in the head and tail is consistent with the pole shifts and anterior pole disorganization observed in *nr4A* RNAi.

These data suggest that DV patterning as a whole is not affected by *nr4A* RNAi, and that the ectopic eyes in *nr4A* RNAi are likely not due to a DV patterning abnormality. The changes in the expression DV boundary markers (*laminB*, NB.22.1e) in the head and tail of *nr4A(RNAi)* animals (Figure 2C, D) reflect more internal shifts of anterior and posterior tissues that occur subsequent to similar shifts in head and tail PCG domains.

> d\) Can the authors demonstrate head/tail enrichment of the genes that are downstream of NR4A? Three (of 100) are claimed to be head/tail enriched (subsection "nr4A regulates the expression of muscle-specific markers and head and tail PCGs", second paragraph), but this isn\'t entirely convincing by eye. Is head/tail enrichment supported for this gene set in other available datasets (e.g. Stückemann, et al)? If the \~100 genes differentially regulated after nr4a(RNAi) are largely not head/tail enriched, this could also support a model where nr4a is acting everywhere in some process that is first manifested phenotypically in the head/tail.

We improved the figure representation of images to more clearly show the expression of some targets at head/tail ends (Figure 5B, Figure 5---figure supplement 1A). We also analyzed the expression levels of the NR4A targets in different segments of the AP axis using expression data from Stückemann et al., 2017 and observed that one-third of them have enriched expression in the head and tail (Figure 5---figure supplement 1B). We note that *nr4A* RNAi also affected the expression of the broadly expressed epidermal gene dd_950 (*vim*) at the ends (Figure 5B, Video 1, 2). That some NR4A-regulated genes were expressed and affected more broadly than only at the ends does not necessarily contradict the model that *nr4A* is required for patterning processes occurring specifically at the ends of the AP axis. We find it interesting that some of the targets display expression at the ends of the axis and these are good targets for future work.

> e\) Did the authors test the function of other new pole genes in tissue patterning, such as the candidate secreted molecule kallman1? The section uncovering new pole genes makes a somewhat abrupt transition to nr4a given that this group has the leading expertise and screening all twelve anterior-pole-enriched genes requires minimal resources. I think a comment could be made about what work was performed that led to analysis or nr4a, especially if other anterior-pole genes did not produce phenotypes.

We did perform RNAi on the anterior pole genes shown in Figure 1B. We were very intrigued by dd_13188 (*kallman1*), but its RNAi did not yield a phenotype. Besides *nr4A* RNAi, dd_7911 (*ror1*) RNAi resulted in lateral ectopic eyes. We decided early on in this work to focus on *nr4A* because we found its patterning phenotype exciting.

> f\) The authors should quantify the results in Figure 4C and Figure 6C (e.g. \# of fibers in an orientation per unit distance as per Scimone, et al., 2017). This would boost the conclusion that muscles are structurally normal in nr4A(RNAi) animals at the early time point (6C) and that defects are head-specific later (4C).

We quantified the number of circular and longitudinal fibers per unit distance, as in Scimone et al., 2017 (Figure 6B, Figure 6---figure supplement 1B). Whereas there was drastic and broad muscle fiber loss in the head tips of *nr4A(RNAi)* animals after prolonged RNAi (9 weeks), no significant reduction in the number of circular or longitudinal muscle fibers were detected in the trunk or tail of *nr4A(RNAi)* animals compared to control animals. At an earlier RNAi time point (4 weeks), no significant differences in the number of circular and longitudinal fibers per unit distance were detected in the head of *nr4A(RNAi)* and control animals (Figure 6---figure supplement 1B). This confirms our findings that the muscle fiber loss is a late manifestation of the phenotype, and that such loss is concentrated at the head tip, and not the midbody or the tail, which is consistent with the reduction in the number of *collagen*^+^ cells in the head (Figure 6C).

> g\) Can the authors clarify the muscle phenotypes in Figure 4C? The text claims \"reduced body wall muscle in the head\" which seems clear from the 9w dorsal but not ventral images which-if anything-show stronger staining in the nr4a(RNAi) animal. Also the method for counting cells in this panel is unclear. Number of cells per what area/volume? What region was counted and how was the tip defined?

Appropriate changes were made in the text to describe more specifically the loss of circular, longitudinal, and diagonal muscle fibers in the head (subsection "Long-term nr4A RNAi causes head-specific reduction in muscle progenitor incorporation", first paragraph), and better quality images of ventral muscle fibers in 4- and 9-week control(RNAi) animals were included (Figure 6A). The method for quantifying *collagen*^+^ cells in Materials and methods has also been included in Figure 6C legend for reference (190mm x 125mm area through the entire DV axis) and the regions quantified are indicated on the figure (Figure 6C).

> 2\) The presentation of data in Figure 5 and Figure 5---figure supplement 1 was difficult to follow and likely will be challenging for someone outside of the planarian field. A diagram or set of diagrams showing how each domain shifts and changes size (for the significant results only) would dramatically improve the reader\'s ability to integrate all of these different factors and get a global picture of what is happening after loss of nr4A.

We thank the reviewers for the suggestion. A figure has been created to integrate and summarize the significant PCG domain shifts that occur during *nr4A* inhibition (Figure 3D).

> a\) Do trunk domains (e.g. ndl-3, ptk-7) change in size after nr4A(RNAi)? Since the animals were all cropped, it was hard to get a sense of this. Based on the other results, I suspect the trunk might be shortened, but it would be helpful to know for sure.

We have included figures of body-wide *ndl-3* and *ptk-*7 expression and quantified the distance between the posterior boundary of the *ndl-3* expression domain and the tail tip as well as the AP length of the *ptk-7* expression domain, normalized to animal length (Figure 3---figure supplement 3A, Supplementary file 1D). We observed no significant differences in these measurements between *nr4A(RNAi)* and control animals (Figure 3---figure supplement 3A, Supplementary file 1D). Furthermore, we performed additional quantifications of the distance (normalized to animal length) of the posterior boundaries of *ndl-2, ndl-5*, and *wnt2* expression domains from the head tip and observed no differences between control and *nr4A(RNAi)* animals (Supplementary file 1D). This shows that while *nr4A* inhibition changes PCG expression domains at the ends of the AP axis, PCG expression in the trunk remains relatively intact.

> b\) It would be helpful at the end of the section to recap and bring all of the data together into a coherent conclusion. Are all domains shifting toward the trunk? Is the trunk diminished due to expanding poles? Are the data incongruous with different trends for different molecules even in the same space? Are boundaries between domains more blended/overlapping after nr4A(RNAi) or is the overall setup of polarity genes the same, just distorted in ratios/sizes?

We agree that this is a helpful analysis/summary to have in the paper and we have endeavored to accomplish this with a diagram as suggested (Figure 6D) and text additions to the Results and Discussion (subsection "Long-term nr4A RNAi causes head-specific reduction in muscle progenitor 328 incorporation\", subsection "A phenotype that fails to reach a stable pattern", fourth paragraph).

> 3\) Could the authors expand their interpretation/description of where nr4a fits in the cell signaling and gene regulatory logic underlying anterior-posterior patterning in planarians? The last figure (Figure 7E) provides a nice description of the nr4a phenotype, but a mechanistic model (perhaps in addition to the existing summary) of how this transcription factor regulates patterning would be helpful. In the Discussion, the authors touch on known roles of NR4A homologs in ligand-independent processes. Given the striking difference between homeostasis and regeneration in nr4a(RNAi) phenotypes, do the authors think nr4a functions autonomously? Or, does nr4a function depend on regional signals? Is it possible to address this question experimentally? For example, what happens to nr4a expression after manipulating other genes involved in cell signaling, such as ndk, fz5/8-4 or wntA? nr4a appears to function as a key intermediary and without its function, differentiation of pole cells shifts anatomically. It would be interesting to explore how the nr4a expression domain behaves in reciprocal experiments to those presented in Figure 5 (i.e., knocking down patterning genes and inspecting nr4a expression to determine if it changes).

Our primary mechanistic model for how nr4A regulates head and tail patterning focuses on the cellular and patterning gene expression change steps that underlie the phenotype. We have now enhanced this cellular model by further study of eye progenitor targeting to progressively posterior eyes and anterior eye decay (Figure 9A, B, Figure 9---figure supplement 1), and by further characterization of PCG expression domains (Supplementary file 1D).

We investigated how nr4A might fit with other patterning genes by examining nr4A expression in animals undergoing *ndk, fz5/8-4, wntA*, and *foxD* RNAi and observed no overt changes in nr4A expression pattern when these PCGs were inhibited and when anterior patterning was disrupted (Figure 3---figure supplement 2). We also detected no significant differences in body-wide nr4A expression by qPCR in *foxD(RNAi)* animals with absent poles compared to control animals (Figure 3---figure supplement 2B). These data suggest that while nr4A regulates pole placement and head and tail PCG expression patterns, it is likely not itself regulated by regional PCG signaling and may function autonomously in muscle.

> 4\) nr4a (dd-Smed_v4 or 6_12229) appears to be differentially expressed following myoD RNAi (48 hpa). We did not peruse other gene lists, such as those derived from single muscle cell RNA-seq studies, but the myoD result indicates that the tissue fragment single-cell RNA-seq approach taken in this paper was important and necessary for uncovering additional pole genes. The authors could discuss whatever links may exist between this work and their previous studies.

The decrease in *nr4A* expression (p-value = 0.021) following *myoD* RNAi at 48 hpa (Scimone et al., 2017) should be interpreted with caution. Such decrease is not observed at earlier *myoD* RNAi time points (0hpa, 6hpa, or 24hpa) (Scimone et al., 2017). The decrease in *nr4A* expression only at 48hpa in *myoD(RNAi)* animals could reflect a difference in the amount of regenerated tissue in control and *myoD(RNAi)* animals, since *myoD* RNAi results in the complete block of regeneration after amputation, including the absence of both poles.

Our head tip fragment RNA sequencing approach offered a more precise spatial isolation of regions/cells to be sequenced than the single-cell RNA sequencing strategies in Scimone et al., 2016, and Fincher et al., 2018, which compared gene expression levels in broader anterior versus posterior segments. Furthermore, our sequencing of regenerating blastemas also aided in the identification of regionally enriched genes when paired with the uninjured animal data. In addition, due to the limited depth of single-cell RNA sequencing, we believe our bulk, regionally specific RNA sequencing strategy was better able to identify genes with low expression levels in uninjured animals, like *nr4A*. In fact, only \~10% of the single-muscle cells in Fincher et al., 2018, had detectable levels of *nr4A* expression, and most of the read counts ranged from 1-4. We have included new SCDE analysis of the *nr4A*^+^ muscle vs. *nr4A*^-^ muscle from Fincher et al., 2018, which showed that *collagen*-encoding genes were enriched in *nr4A*^+^ muscle, but no muscle subtype transcription factor genes, like *myoD* or *nkx1-1*, were differentially expressed (Supplementary file 1E).

We have also linked our findings with the muscle cell subtype clustering in Scimone et al., 2018, and showed that *nr4A* is expressed broadly in body-wall muscle, but not in intestinal or pharyngeal muscle (Figure 4E). Additionally, we showed that *nr4A* expression within body-wall muscle cluster is not concentrated preferentially in circular, longitudinal, or DV fibers (Figure 4---figure supplement 1), which is consistent with our finding that *nr4A* inhibition leads to general fiber loss at the head tip.
